Review

Ruminant Milk-Derived Extracellular Vesicles: A Nutritional and Therapeutic Opportunity?

Siew Ling Ong 1,*, Cherie Blenkiron 2,3, Stephen Haines 4*, Alejandra Acevedo-Fani 5, Juliana A. S. Leite 5*, Janos Zempleni 6, Rachel C. Anderson 1,5 and Mark J. McCann 1,5,*

1 Smart Foods Innovation Centre of Excellence, Te Ohu Rangahau Kai, AgResearch Ltd., Massey University Campus, Palmerston North 4410, New Zealand; rachel.anderson@agresearch.co.nz
2 Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1051, New Zealand; c.blenkiron@auckland.ac.nz
3 Auckland Cancer Society Research Centre, University of Auckland, Auckland 1051, New Zealand
4 Beyond Food Innovation Centre of Excellence, AgResearch Ltd., Lincoln 7674, New Zealand; stephen.haines@agresearch.co.nz
5 Riddet Institute, Massey University, Palmerston North 4442, New Zealand; a.acevedo-fani@massey.ac.nz (A.A.-F.); J.Leite@massey.ac.nz (J.A.S.L.)
6 Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA; jzempleni2@unl.edu
* Correspondence: SiewLing.Ong@agresearch.co.nz (S.L.O.); Mark.McCann@agresearch.co.nz (M.J.M.)

Abstract: Milk has been shown to contain a specific fraction of extracellular particles that are reported to resist digestion and are purposefully packaged with lipids, proteins, and nucleic acids to exert specific biological effects. These findings suggest that these particles may have a role in the quality of infant nutrition, particularly in the early phase of life when many of the foundations of an infant’s potential for health and overall wellness are established. However, much of the current research focuses on human or cow milk only, and there is a knowledge gap in how milk from other species, which may be more commonly consumed in different regions, could also have these reported biological effects. Our review provides a summary of the studies into the extracellular particle fraction of milk from a wider range of ruminants and pseudo-ruminants, focusing on how this fraction is isolated and characterised, the stability and uptake of the fraction, and the reported biological effects of these fractions in a range of model systems. As the individual composition of milk from different species is known to differ, we propose that the extracellular particle fraction of milk from non-traditional and minority species may also have important and distinct biological properties that warrant further study.

Keywords: milk; extracellular vesicle; exosome; ruminant; MISEV

1. Introduction

Milk is the only food that has evolved to meet the nutritional needs of newborns, supporting growth and development while also being a significant source of nutrients in adults [1–3]. The domestication of livestock was a pivotal step in the consumption of non-human milk which has become a substantial source of essential nutrients in many diets globally [4–6]. To meet this demand, the production of milk increased from 708 million tonnes in 2009 to 883 million tonnes in 2019, with cow and buffalo milk accounting for 81% and 15% of production, respectively (Supplementary Table S1) [7].

In early life, major milk components such as lactose (energy source), minerals (musculoskeletal development), and high-value biological proteins provide essential nutrition [8,9]. Milk consumption throughout life can also address malnutrition and can represent a significant proportion of overall nutrient intake in developing nations [10].

While the milk macro- and micronutrient composition is largely well established, there is considerable interest in milk-derived extracellular vesicles (EVs) and their cargoes
as a source of nutrients in the classical sense, such as nucleosides, and amino acids, or as a nutritional component that influences biological functions by regulating biochemical pathways and/or interactions with the host’s gut microbiome [11–18]. Evolutionary theory suggests that milk-derived EVs and their cargoes must have a biological purpose to justify the metabolic cost required to produce them during lactation.

Our review covers the following: a summary of the nutritional composition of the types of milk that have been used to study milk-derived EVs, the nature and composition of these vesicles and their cargoes, the evidence for their stability and uptake in the gastrointestinal tract, their reported biological effects, and some of the key challenges in using them for studies. Methods used to identify peer-reviewed studies are shown in Figure 1. Our review excludes any studies on plant-derived milk alternatives.

Figure 1. Schematic diagram for selection of included studies.

2. Nutritional Composition of Milk

Milk from minority dairy species, i.e., not cow milk, is more widely consumed in regions with a harsh environment which requires animals with specific adaptations [9]. It has generally not been studied in as much detail for nutrition or bioactivity as cow milk despite the evidence of substantial compositional differences in the different types of
proteins, lipids, micronutrients, and bioactive components between milk from different species. The macronutrient composition of milk from different mammals has been extensively studied and is readily available in the public domain. A list of the milk composition from different mammals is collated in Table 1, based on the different quantification methods used and data reporting across different databases (the conversion can be found in Supplementary Table S2).

Table 1. Gross composition of milk of different mammals obtained from available food composition databases. Data are presented as an average (±standard deviation) per 100 g.

| Species     | Energy (kJ) | Carbohydrate (g) | Fat (g) | Protein (g) | Water (g) | Ref.                  |
|-------------|-------------|------------------|---------|-------------|-----------|-----------------------|
| Buffalo     | 473 (66)    | 4.9 (0.4)        | 8.3 (1.4)| 4.7 (1.3)   | 80.9 (2.2)| [19–21]              |
| Camel       | 273 (42)    | 4.2 (1.6)        | 3.8 (0.4)| 3.6 (1.3)   | 87.6 (2.2)| [19,21,22]          |
| Cow (>3% fat)| 277 (22)    | 4.7 (0.5)        | 3.8 (0.5)| 3.3 (0.2)   | 87.3 (0.7)| [19,20,22–27]       |
| Cow (1–2.9% fat) | 196 (14)   | 4.9 (0.1)        | 1.5 (0.4)| 3.4 (0.2)   | 89.6 (0.3)| [19,22–27]          |
| Cow (<1% fat)| 151 (7)     | 4.9 (0.2)        | 0.2 (0.2)| 3.6 (0.2)   | 90.3 (0.6)| [19,22,23,25–27]    |
| Donkey      | 175         | 6.1              | 1.0     | 2.0         | 90.4      | [19]                 |
| Goat (>3% fat)| 288 (39)   | 4.6 (0.3)        | 0.7     | 3.4 (0.4)   | 87.5 (1.5)| [20,22–26]          |
| Goat (<3% fat)| 212        | 3.9              | 2.4     | 2.7         | 90.2      | [24]                 |
| Horse       | 177         | 5.4              | 1.1     | 2.1         | 91.0      | [28]                 |
| Sheep       | 406 (16)    | 4.9 (0.2)        | 6.2 (0.5)| 5.6 (0.3)   | 82.7 (0.6)| [22,23,26]          |
| Human       |             |                  |         |             |           |                      |
| Colostrum   | 242 (7)     | 6.8 (0.3)        | 2.6 (0.0)| 2.0 (0.1)   | 88.2 (0.0)| [22,23,29]          |
| Transitional| 267 (18)    | 6.7 (0.2)        | 3.4 (0.5)| 1.5 (0.1)   | 87.1 (0.6)| [19,23,26]          |
| Mature      | 293 (9)     | 7.3 (0.7)        | 4.2 (0.2)| 1.2 (0.1)   | 87.3 (0.3)| [19,22,23,25,27]    |

2.1. Carbohydrate

Lactose is the primary carbohydrate in milk, providing 30% to 60% of energy depending on the species of milk [10,30–32]. It also enhances intestinal mineral absorption (e.g., calcium, sodium, magnesium, and phosphorus), utilisation of vitamin D, and stool softness [4,10,30,33]. Hydrolysis of lactose by the enzyme lactase into a simpler form of sugars is essential for intestinal absorption in humans [10,34]. Lactase deficiency contributes to the fermentation of lactose in the colon by microorganisms, producing gases (hydrogen, carbon dioxide, and methane), organic acids (acetic, butyric, and propionic acid), and excess water in stool, leading to uncomfortable bowel activity such as diarrhoea, flatulence, and bloating [1,10,35,36].

Many forms of oligosaccharides are also present in milk, contributing to the gut microbiome diversity in infants [17]. In humans, milk oligosaccharides are the third most abundant macronutrients (7 to 20 g/L) after lactose and lipids [31,37], but in other mammals, the milk oligosaccharides content is 10 to 100 times lower [37].

2.2. Fat

Milk fat occurs in emulsified droplets known as milk fat globules (MFGs) that are mainly triacylglycerols (97–98% of total lipids by weight, including a large number of esterified fatty acids and phospholipids), as well as proteins and fat-soluble vitamins [10,38]. The tri-layered phospholipid membrane of an MFG is designed to protect its contents from lipolysis and oxidation [38]. The roles of milk lipids and MFGs in health have recently been reviewed [39,40]. German and Dillard [41] reviewed the composition, structure, function, absorption, and bioactivity of human and cow milk lipids, noting the importance of considering the role of MFGs.

In general, the lipid composition of milk fat also differs from one species to another. Zou et al. [42] compared the lipid composition of five mammalian milks (cow, buffalo, donkey, sheep, and camel) to human milk by evaluating the degree of the chemical similarity of the samples. This showed that although the total fatty acid composition of certain non-human milks was highly similar to that of human milk (e.g., 96.4% similarity in sheep’s
milk), there were substantial differences when it came to the individual chemical species (e.g., only 20.2% similarity in polyunsaturated fatty acids of sheep’s milk). Devle et al. [43] measured the fatty acid profiles in the milk of three ruminants (cow, goat, and sheep) and two non-ruminants (donkey and horse) and found a substantial diversity in the occurrence and abundance of them between species and their degree of correlation with health attributes.

2.3. Protein

Depending on the species, there is between 1.2 and 5.6 g of protein per 100 g of milk. Caseins ($\alpha$-s1-, $\alpha$-s2-, $\beta$-, and $\kappa$-casein) are the most abundant insoluble proteins in milk [44,45]. The soluble proteins in the whey fraction of milk mainly consist of soluble milk serum proteins ($\beta$-lactoglobulin, $\alpha$-lactalbumin, immunoglobulins, serum albumins, etc.), protease peptones (casein-derived low-molecular weight peptide and protease peptone component 3), and membrane proteins (i.e., milk fat globule membrane (MFGM)) [10,44,46,47].

The unique ability of milk caseins to form macromolecule aggregates (casein micelles) with minerals such as calcium and phosphorus improves the bioavailability, delivery, and intestinal absorption of these minerals [4]. The industrial importance of ruminant milk proteins in cheese production and secondary transformation products has led to the extensive study of these components, such as the proteomic analysis of several forms of milk: as a whole [45], the whey fraction [48,49], and sub-fractions of whey such as caseins [50] and MFGMs [51–54].

Roncada et al. [55] reviewed advancements and challenges in the proteomic analysis of milk from farm animals, together with an overview of the different components in the milk fractions. Similarly, Malacarne et al. [56] systemically reviewed the composition of horse, human, and cow milk from the perspective of protein and lipid fractions, proposing that the nourishment provided by horse milk is more similar to human milk than that provided by cow milk.

2.4. Micronutrients

Micronutrients are essential nutrients that cannot be synthesised by humans and must be provided through our diet or other means [57]. The consumption of two to three servings of milk or milk products provides the required nutrient intakes for several important micronutrients (calcium, magnesium, selenium, riboflavin, vitamin B12, and pantothenic acid) [10]. Milk has comparatively fewer absorption inhibitors (e.g., oxalate and phytates) than other foods, which improves the bioavailability and absorption of these micronutrients [8,10].

The major milk minerals, calcium and phosphorus, which are required for optimal bone health are more bioavailable due to the mineralisation of casein micelles in both the insoluble organic colloid and mineral forms [58]. Medhammar et al. [9] highlighted the differences between the mineral profiles of different milk species, with moose and reindeer milk having the highest concentration of most essential minerals, and horse and donkey milk having the lowest. Milk also provides water- and fat-soluble vitamins due to the dual-phase matrix of lipid micelles suspended in the aqueous environment. Milk vitamin profiles are broadly consistent, with vitamin C having the highest concentration, and vitamins B12 and D having the lowest concentrations, with some species differences [9,59]. Graulet [57] reviewed the role of ruminant milk, with an emphasis on cow’s milk, in meeting the required vitamin consumption by humans.

2.5. Other Milk Components

Admyre et al. [60] identified the presence of immune-modulatory exosomes in human milk which led to research into how exosomes (one type of EV) and their cargoes may have a role in inter-cellular, inter-individual, or inter-species communication. There has been substantial interest in milk-derived EVs as a novel bioactive fraction of milk [11,12,16,61–63].
However, the majority of research has focused on human or cow’s milk, and not minority dairy species, and therefore this paper reviews the key technical challenges and reported biological activities of ruminant and pseudo-ruminant milk-derived EVs.

3. Milk-Derived EVs

According to the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) guidelines, “extracellular vesicle is the generic term for any particle naturally released from the cell that is delimited by a lipid bilayer and cannot replicate, i.e., do not contain a functional nucleus” [64]. Due to historical differences in how these vesicles were isolated, characterised, and named, the guidelines recommend using the term “extracellular vesicle” instead of other terms such as “exosome” or “microvesicle”, except when the biogenesis or release pathway is investigated [64]. However, in this review, the terminology used in the original paper cited will be used. The MISEV guidelines provide experimental and reporting guidelines specific to the field of EVs [64–66], and several curated public knowledgebases promote the transparency and reproducibility of EV experimental studies [67–75]. Recent advances in the use of flow cytometry to study EVs have led to a standardised experiment and reporting framework (MIFlowCyt-EV) [64,76,77].

EVs are heterogenous populations that are categorised based on their biogenesis pathway. In brief, exosomes (~30 to 150 nm) originate from the intraluminal vesicles via the endosome trafficking pathway, while microvesicles (100 nm to 1 µm) result from direct budding from the plasma membrane of the parental cell, and apoptotic bodies (1 to 5 µm) are shed from cells undergoing apoptosis [78,79]. To date, most of the available methodologies cannot isolate a pure subpopulation of EVs; therefore, a defined mixed population is widely used for studies. The progress in understanding EV biology in the context of inter- or intra-species signal mediators, due to their diverse cargo (mRNA, miRNA, protein, etc.), has spawned a growing interest among the research community. An in-depth review of EV heterogeneity [78] and cell biology [80] proposed a need for a clear definition of the different subpopulations, based on cargo composition, trafficking pathways, and biological functions. Several other detailed reviews focused on other aspects of EVs such as biogenesis [81,82], delivery or target mechanisms [83–85], and current advances in knowledge [86]. The majority of publications on EVs have been focused on human growth, development, homeostasis, and disease progression, and several other reviews of milk-derived EVs are summarised in Table 2.

| Authors          | Scope of Review                                                                 | Ref.        |
|------------------|---------------------------------------------------------------------------------|-------------|
| Galley et al.    | Update on the therapeutic potential of human milk-derived EVs in disease, with an emphasis on necrotising enterocolitis. | [11]        |
| Sanwlani et al.  | Discussed the mediator role of milk-derived EV crosstalk from inter-cellular to cross-species and highlighted the emerging therapeutic potential of milk-derived EVs. | [12]        |
| Melnik et al.    | Reviewed epidemiological and translational evidence on how dairy milk-derived exosomes (along with their cargo) contribute to the pathogenesis of common Western diseases. | [13]        |
| Munir et al.     | Highlighted the role of food-derived exosomes on human physiological and pathological events, as well as their potential as a therapeutic agent. | [14]        |
| Zempleni et al.  | Discussed the bioavailability and the distribution of milk-derived exosomes and their cargo (emphasis on miRNA). | [63]        |
| de la Torre et al.| Summarised the general biophysical features and roles in health and disease of EVs. The authors also focused on human breast milk-derived exosomes in maternal and infant health, based on an in-depth discussion on two proteomic datasets of human breast milk exosome studies. | [16]        |
| Le Doare et al.  | Discussed the role of human milk microbiota, milk oligosaccharides, and EVs in the development of the infant gut microbiome and immune system. | [17]        |
| Foster et al.    | Summarised the knowledge about EVs derived from human biofluids, with emphasis on the human reproductive system. | [18]        |
3.1. Isolation of Milk-Derived EVs

From complex biofluids to simpler in vitro cell culture media, different isolation methods may be employed to minimise the presence of unwanted artefacts which could jeopardise the downstream analysis. Review articles or book chapters on EV isolation techniques are readily available in the literature, from providing a brief overview [87–92] to a comprehensive discussion [93–96].

EVs’ isolation relies on their separation from contaminants such as proteins and other particles through the use of known biophysical and/or biochemical properties: size, buoyant density, surface charge, surface molecules’ expression and their composition. Several articles dedicated to a specific scope of isolation techniques are worth mentioning. Li et al. [97] discussed the different isolation strategies for human biofluid-derived EVs which have been employed in mass spectrometry (MS)-based proteomic studies for the past decade (2009–2019). Another review article highlighted the usefulness of size exclusion chromatography (SEC) in EV isolation, given that this approach is highly scalable and adaptable while maintaining the EVs’ characteristics [98]. A three-step filtration protocol comprising dead-end filtration, tangential-flow filtration, and track-etched membrane filtration was proposed by Heinemann and Vykoukal [99] to provide an approach to concentrate and fractionate samples with minimal forces applied on EVs. The progression in microfluidics-based platforms in the past decade has enabled the rapid separation of EVs from small sample volumes. A review by Meng et al. [100] highlighted the interesting advancements in the microfluidic separation of EVs based on the different separation principles.

Characterisation of isolated EVs still largely uses immunochemical (e.g., ELISA, Western blot), MS-based, and optical (e.g., nanoparticle tracking analysis (NTA), microscopy, and flow cytometry) methods. However, any of the single aforementioned detection approaches may not be sufficient to address the issues of specificity, efficiency, and consistency in EV detection. More often, multiple detection approaches are employed within the research community when it comes to EV characterisation. The progression in analytical sciences has pushed for the development of new and innovative instruments to meet the aforementioned challenges. Recent review articles have summarised the emerging new technologies available that are specifically developed for EV characterisation [94,101–104].

Methods for the isolation and characterisation of milk-derived EVs have no significant differences compared to those for isolation from other biofluids or cell culture media; thus, any protocol, technique, or technology for isolation of EVs of different origin can also be used for those from milk. The only difference between these types of samples is the unwanted artefacts present in different biofluids (e.g., lipoproteins in blood serum, or casein aggregates in milk). A simple method for isolating EVs from breast milk was described by Wang [50], which only requires a proprietary precipitation reagent (ExoQuick), a benchtop centrifuge, and a few common lab consumables; however, this method isolates a crude preparation of EVs. Several other approaches have been developed and used to study EVs (Table 3).

| Species | Methodology | Findings | Ref. |
|---------|-------------|----------|------|
| Human   | DC + PR     | Extracellular Vesicle EV isolation from human milk via precipitation using ExoQuick.          | [105,106] |
| Human   | DC + top-down DG-UC, DC + bottom-up DG-UC | DC + top-down DG-UC was efficient and reproducible with a heterogeneous population of EVs (sizes and types). | [107] |
| Cow     | UC, SEC, PR, membrane affinity column, PS-affinity isolation | SEC-based qEV column (Izon Science) yielded high purity (high EV count per mg protein) and a large amount of RNA with minimal operation time. | [108] |

Table 3. Methods used to study EVs and exosomes from milk.
### Table 3. Cont.

| Species     | Methodology                                      | Findings                                                                                                                                                                                                                                                                                                                                 | Ref. |
|-------------|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Cow         | DC + UC, DC + EDTA + UC, DC + DG-UC              | DC + DG-UC yielded the highest abundance of miRNA with EV surface protein markers. EV concentration was significantly higher for samples treated with acidification, suggesting efficient removal of casein. However, acidification was reported to partially degrade EV surface proteins (i.e., CD9 and CD81). TEM images revealed a rough surface of EVs isolated with acids. | [109]|
| Cow         | UC, HCl or AA                                    | EV concentration was significantly higher for samples treated with acidification, suggesting efficient removal of casein. However, acidification was reported to partially degrade EV surface proteins (i.e., CD9 and CD81). TEM images revealed a rough surface of EVs isolated with acids. | [110]|
| Cow         | AA+UC, C + UC                                    | AA+UC method yielded lower protein content, but EV protein markers (CD81, Rab5B, TSG101, and Hsc70) were reported to be present in high abundance. Proteome analysis revealed C/UC EV fraction contains whey proteins such as casein, albumin, lactoferrin, and lactoglobulin. | [111]|
| Cow         | Total particles and Annexin V⁺ particles measured using flow cytometry (Canto II and Cytoflex) and NTA (NanoSight) | Significant correlation of total particle counts using Cytoflex and NanoSight and for Annexin V⁺ particles using Canto II and Cytoflex.                                                                                                                                                                                      | [112]|
| Cow + HCT 116 cell line + Ascaris suum | AFM-based force spectroscopy (FS)               | Demonstrated an AFM-based characterisation strategy with the ability to discriminate EVs from contaminants.                                                                                                                                                                                                                   | [113]|
| Human       | Novel solid-phase extraction in tip-based format |                                                                                                                                                                                                                                                                                                                                                                                                   | [114]|
| Cow         | UC, IP                                           | IP had a better efficiency in removing casein and reduced operator time. TEM revealed precipitated exosomes had rough surfaces. Other features of exosomes isolated were not significantly different.                                                                                                                                                                   | [115]|
| Cow         | DC + DG-UC, DC + SEC                             | Increased yield and better purity of intact exosomes with DC + SEC method. PR alone and Filtration + UC unsuitable due to the species difference. UC + PR was useful for rapid isolation with increased recovery. UC + DG-UC suitable for efficient purification with native form intact. Evaluation of Vaswani et al. [116] on human milk. The enrichment profile of exosomes was similar to that obtained in cow milk in their previous study, suggesting the method was suitable for use on human milk. | [116]|
| Human + Cow | DC + SEC                                         | Isolation and characterisation of EVs from both milks compared to conventional UC.                                                                                                                                                                                                                                           | [118]|
| Human + Cow | UC (milk serum) + SEC, C+ UC (fluff layer) + SEC |                                                                                                                                                                                                                                                                                                                                                                                                   | [119]|

The terminology used is based on the reference cited, and this division reflects older thinking and is a “pool” of EVs that are responsible for the effects (AA, acetic acid; AFM, atomic force microscopy; C, centrifugation; DC, differential centrifugation; DG-UC, density gradient ultracentrifugation; EDTA, ethylenediaminetetraacetic acid; IP, isoelectric precipitation; NTA, nanoparticle tracking analysis; PR, precipitation reagent; PS, phosphatidylserine; SEC, size-exclusion chromatography; UC, ultracentrifugation).

#### 3.2. Protein Composition of Milk-Derived EVs

The application of MS-based proteomic profiling and protein quantification has been of substantial significance in EV research to allow the identification and quantification of EV proteomes from various cultured systems, organs, body fluids, or plants. Several review articles provide a high-level overview of the MS-based methodological approaches widely used in EV studies [79,120–123]. MS-based proteomic quantitative analysis can be achieved
with either a labelled (e.g., isobaric tags for relative and absolute quantification (iTRAQ); stable-isotope labelling of amino acids (SILAC)) or label-free approach which quantifies proteins based on their spectral intensity or counts [79,120]. Data generated from MS consist of large datasets with functional analysis of these data needed for the identification of biological processes, which includes the Gene Ontology (GO) term annotation, enrichment analysis, and/or pathway analysis [124].

The early discovery of several EV-enriched protein markers (tetraspanins, heat shock proteins, annexins, etc.) from isolated EVs derived from in vitro cell models using MS-based proteomic characterisation occurred in the early 2000s [125–127]. Admyre et al. [60] first reported the investigation of the mammalian milk-derived EV proteome using a tandem MS approach to verify several important EV protein markers (tetraspanins, heat shock proteins, MUC-1, etc.) from the human colostrum and mature breast milk-derived exosomes, respectively. Building on this, Reinhardt et al. [128] identified 2107 proteins in a comprehensive study of cow milk-derived exosomes by utilising two-dimensional liquid chromatography-based separation coupled with tandem mass spectrometry. These studies led to several characterisation papers, summarised in Table 4 [128–137]. The literature demonstrates that milk-derived EVs have a distinctive proteome compared to other milk fractions and that a significant proportion of these proteins have reported immune-regulatory properties.

Table 4. Major findings of analytical techniques used to characterise the protein composition of milk-derived EVs and exosomes.

| Species   | Technique         | Findings                                                                 | Ref.                      |
|-----------|-------------------|--------------------------------------------------------------------------|---------------------------|
| Human     | µLC-MS/MS         | Extracellular Vesicle
Identified 258 EV membrane surface proteins (surfaceome) that contributed to antiviral activity. | [138]                     |
| Human     | nLC-MS/MS, LC-MS/MS | Found 2698 unique proteins (633 previously reported in EVs).           | [130]                     |
| Human     | nLC-MS/MS         | Identified 73 proteins and the presence of several exosomal protein markers. | [60]                      |
| Cow       | CDMS vs. nLC-MS/MS | Detected 57,350 particles in 8 distinct subpopulations (2D Gaussian model). nLC-MS/MS data corroborated exosome enrichment in CDMS samples and identified 162 proteins and 43 exosome-specific proteins. Identified 1330 proteins (118 unique to infection) in bovine leukaemia virus (BLV)-infected cattle. | [131]                     |
| Cow       | nLC-MS/MS         | Presented 3 proteomic datasets of milk-derived EVs from healthy and BLV-infected cattle. | [139,140]                 |
| Cow       | nLC-MS/MS         | Identified 1899 proteins (20 and 41 specific to 35 K and 100 K pellets, respectively). | [132]                     |
| Cow       | nLC-MS/MS         | A novel subset of EVs with unique proteins and other cargoes.           | [133]                     |
| Camel     | nLC-MS/MS         | Identified 1010 functional groups of proteins. Total of 890 proteins in all 3 species, with 5 specific to C. dromedaries, 31 to C. bacterianus, and 12 to hybrid camels. | [134]                     |
| Cow + donkey + goat | UHPLC-HRMS | Metabolomic analysis of 5 different pools of fractions obtained from differential centrifugation from 3 different species. | [141]                     |
Table 4. Cont.

| Species   | Technique                          | Findings                                                                                      | Ref.  |
|-----------|------------------------------------|----------------------------------------------------------------------------------------------|-------|
| Human     | iTRAQ-labelled, nLC-MS/MS          | Exosome Total of 70 peptides from 28 proteins in preterm milk exosomes differentially expressed compared to full-term milk exosomes, with 47 upregulated and 23 downregulated. | [135] |
| Human + Cow | iTRAQ-labelled, nLC-MS/MS      | Total of 920 proteins identified with 575 proteins differentially expressed between colostrum and mature milk in both species. | [142] |
| Cow       | nLC-MS/MS                          | Insufficient exosomes from saliva and urine for analyses. Validation of TSG101 protein milk and plasma exosomes. Total of 86 proteins unique to milk exosomes and 37 proteins unique to plasma exosomes identified. | [136] |
| Cow       | µLC-MS/MS, 2D LC-MS                | Total of 2971 proteins identified, of which 1490, 302, and 334 were unique to exosomes, whey, and MFGMs, respectively. Total of 90 exosome proteins were differentially regulated by mastitis. | [143] |
| Cow       | iTRAQ-labelled, nLC-MS/MS          | Exosome Total of 2107 proteins identified. Major MFGM proteins were abundant in exosomes but only represented 0.4% to 1.2% of the total exosomal proteome compared to 15% to 28% of that of the MFGM proteome. | [128] |
| Pig       | nLC-MS/MS                          | Total of 2313 peptides from 639 proteins, with 68 novel proteins identified. Identification of exosome-associated proteins, CD81 and CD63, in horse milk. | [129] |
| Horse     | MALDI-ToF                          |                                                                                              | [144] |

The terminology used is based on the reference cited, and this division reflects older thinking and is a “pool” of EVs that are responsible for the effects (µLC-MS/MS, micro-flow liquid chromatography-tandem mass spectrometry; CDMS, charge detection mass spectrometry; iTRAQ, isobaric tags for relative and absolute quantification; MALDI-ToF, matrix-assisted laser desorption ionisation-time of flight; MFGM, milk fat globule membrane; nLC-MS/MS, nano-flow liquid chromatography-tandem mass spectrometry).

3.3. Lipid Composition of Milk-Derived EVs

As different EV subtypes (exosomes, microvesicles, and apoptotic bodies) are categorised, in part, based on their respective biogenesis pathways, the membrane lipid composition of EVs resembles that of the parent pathway [93,145]. Understanding the lipid composition of EVs, such as sphingolipids, ceramides, phosphatidylserine, and the lipid raft component cholesterol, is an essential part of their biology, biogenesis, and biological function [121,146]. Several of the analytical chromatography and mass spectrometry techniques routinely used in EV proteomics have also been used for the qualitative and quantitative assessment of EV lipids. The challenges, limitations, and current knowledge of EV lipidomics have been reviewed elsewhere [121,145,147–150].

There are particular challenges in isolating lipids from milk-derived EVs due to the co-isolation of milk lipids (i.e., MFGs), and in milk EV isolates with a high triacylglycerol content (TAG), since MFGs contain a greater amount of TAGs in their core than EVs [38,119], potentially interfering with accurate EV lipidomic studies. In this review, MFG lipidomic studies are not included because the biophysical properties (tri-layered membrane) and cargoes of MFGs are distinctly different from those of EVs.

To date, two studies have specifically examined the lipid composition of EVs [119,151]. Blans et al. [119] successfully applied size exclusion chromatography to human and cow milk samples to isolate distinct fractions of EVs and MFGs; these were partly characterised by the notably higher TAG-to-cholesterol ratio in human and cow MFGMs in MFGs when compared to EVs. The authors also reported a higher proportion of sphingomyelin,
phosphatidylserine (PS), and phosphatidylcholine (PC), and a lower proportion of phosphatidylethanolamine (PE) in EVs compared to MFGs. Yassin et al. [151] reported concentrations of ~10 to 15 µg/mL of phosphatidylinositol, PS, and PE, and ~20 to 25 µg/mL of PC in dromedary milk exosomes which were consistent during different lactation periods.

Phospholipids, such as those reported in EVs, have been associated with beneficial health effects [152–156]. We recognise that there is a knowledge gap in the understanding of the lipid composition of mammalian milk-derived EVs, which is essential to understanding the biology of their function and biogenesis mechanisms [157].

3.4. Nucleic Acid Composition of Milk-Derived EVs

Milk-derived EVs contain nucleic acid cargoes, proposed to be derived from mammary epithelial cells, encased within the cytosol of a lipid bilayer vesicle [158,159]. Studies characterising the milk-derived EV transcriptome are summarised in Table 5.

Of interest is the presence of microRNA (miRNA) in milk; these are short nucleic acids of ~22 nucleotides and are known for their role in post-transcriptional regulation. In milk, these miRNAs are present in two main forms: bound to RNA-binding proteins, or encapsulated in EVs [12]. The abundance of miRNAs in milk has generated substantial interest and research into whether these miRNAs are bioavailable and bioactive. Many studies have focused on the potential involvement of milk-derived EV miRNA in inter-cellular crosstalk, inter-individual communication (breastfeeding), and cross-species communication (due to human consumption of other mammalian milk throughout adulthood). However, it is noted that the concept of ingested miRNA from another species surviving digestion and being absorbed in sufficient quantities to elicit a quantifiable biological effect remains to be convincingly shown, despite several promising studies [109,160–162].

Several review articles on milk-derived EV nucleic acid cargoes are available, which include their functional implications [61,163,164] and future applications [165,166]. Additionally, with development in the application of next-generation sequencing (NGS), several nucleic acid profiling studies (with an emphasis on miRNA) have reported their findings from milk-derived EVs in humans [167–173], cows [158,174–179], pigs [129,170,180,181], sheep [182], and buffaloes [183]. In silico insights from these data suggest potential regulation of several key pathways, but for the most part, these predictions have not been validated in vitro or in vivo.

However, the presence of miRNA in milk-derived EVs suggests that they have a potential role as natural or modifiable therapeutic agents to improve or enhance human and animal health. For instance, there are studies evaluating the milk-derived EV transcriptome for use as nanotherapeutic agents [184–186], as disease biomarkers [158,179,187], differential mediators [188,189], and as a health assessment tool for lactating animals [175]. Conversely, the role of milk-derived EVs as a functional regulator has also generated concerns because continuous consumption of dairy may contribute to the pathogenesis of common Western diseases such as type 2 diabetes mellitus, allergies, and cancers [13,190–194].

In brief, there are two broad schools of thought regarding the specific role of milk-derived miRNAs in postnatal development: (1) the functional hypothesis, which proposes that these miRNAs are purposefully transferred by the parent to the offspring to exert meaningful epigenetic regulatory functions in the infant’s development, and (2) the nutritional hypothesis, which proposes that the degradation of miRNAs in the gut during digestion into nucleotides means that they are only nutritional “building blocks” for the infant only and do not exert any meaningful regulatory functions [191].

The studies listed in Table 5 show that: (1) RNA (especially miRNA) is present in milk-derived EVs and other extracellular particles, (2) some of these miRNAs are conserved between species, (3) some of these miRNAs are specifically found in extracellular particles, and (4) biological dysfunction, such as disease, can alter miRNA abundance. On the assumption that conservation of the miRNA sequence implies conservation of function, much of the research into the biological effects of milk-derived EVs has focused on their
miRNA cargoes and their effects on immune regulation. These studies, and others, are reviewed later.

Table 5. Major findings of nucleic acid studies conducted on EVs of different mammalian milk used to characterise the RNA composition of milk-derived EVs and exosomes.

| Species          | Technique | Findings                                                                                                                                  | Ref.  |
|------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Human            | NGS       | Extracellular Vesicle: Total of 1523 miRNAs identified with more than one read in 70% of samples from the Faroe Islands cohort (364 mothers). Total of 55 lncRNAs identified with 11 lncRNA detected in >50% of the breast milk samples and 5 in >90%. The authors suggested the packing of highly correlated lncRNAs is regulated by the same pathway. Total of 5 miRNA stably expressed in all groups. Total of 4 (probiotic) and 5 (atopic dermatitis) miRNAs differentially expressed. No evidence of maternal probiotic ingestion altering miRNA abundance, unlikely for probiotic protective effect to be transferred to the infants. | [195] |
| Human            | qPCR      |                                                                                                                                           | [196] |
| Human + Pig      | qPCR, NGS |                                                                                                                                           | [172] |
| Cow              | qPCR, NGS |                                                                                                                                           | [170] |
| Cow              | qPCR, NGS |                                                                                                                                           | [109] |
| Cow              | qPCR, NGS |                                                                                                                                           | [174] |
| Cow              | Microarray|                                                                                                                                           | [187] |
| Cow              | qPCR, NGS |                                                                                                                                           | [175] |
| Cow              | qPCR      |                                                                                                                                           | [133] |
| Cow + Sheep      | qPCR, NGS |                                                                                                                                           | [182] |
| Human            | qPCR, NGS |                                                                                                                                           | [167] |
| Human            | qPCR, NGS |                                                                                                                                           | [168] |
| Human            | qPCR, NGS |                                                                                                                                           | [173] |
| Human and Pig    | In silico |                                                                                                                                           | [198] |
| Cow              | Qpcr      |                                                                                                                                           | [199] |
| Cow              | PCR, NGS  |                                                                                                                                           | [200] |
### Table 5. Cont.

| Species          | Technique         | Findings                                                                 | Ref. |
|------------------|-------------------|--------------------------------------------------------------------------|------|
| Cow              | qPCR, NGS         | Total miRNAs: 1472 detected, with 480 novel miRNAs. Total of 18 miRNAs differentially expressed due to mastitis. Presented miRNA expression profiles of both healthy and infected cows. bta-miR-223 and bta-miR-142-5 were considered potential early mastitis detection targets. | [158]|
| Cow              | qPCR              | Reported the effects of fermentation on the expression of miR-29b (unaffected) and miR-21 (significantly reduced by fermentation). | [201]|
| Cow              | qPCR, Microarray  | Microarray profiling of miRNA (79) and mRNA (19,320) on exosome obtained via ultracentrifugation and its supernatant. Total miRNAs: 417 detected, with 303 novel miRNAs. Two differential expression analyses revealed 6 miRNAs with significant differential presence. Total of 2 miRNAs were proposed as potential biomarkers for early infection. | [178]|
| Cow              | NGS               | Total miRNAs: 558 detected in all species (buffalo, cow, pig, human, and panda), with the top 10 highly expressed miRNAs conserved across species. Total of 48 miRNAs were differentially expressed in buffalo, compared to other species. | [179]|
| Cow and Buffalo  | NGS, in silico    | Total miRNAs: 558 detected in all species (buffalo, cow, pig, human, and panda), with the top 10 highly expressed miRNAs conserved across species. Total of 48 miRNAs were differentially expressed in buffalo, compared to other species. | [183]|
| Pig              | qPCR, NGS         | Total miRNAs: 491 detected, with 315 novel miRNAs. A random selection of 14 mRNAs among the top 50 was further confirmed using qPCR. | [129]|
| Pig              | qPCR, NGS         | Total pre-miRNAs: 180 detected, with 40 novel pre-miRNAs, corresponding to 237 mature and 234 unique miRNAs. | [180]|
| Pig              | qPCR, NGS         | Immune-related miRNAs are most abundant in colostrum. Stable expression of the casein family genes between mid and late lactation periods. | [181]|
| Camel            | qPCR              | Microvesicle/Nanovesicle Total of 281 miRNAs detected. Expression of miR-181a and miR-17 was detected in CD63-positive human milk exosomes. Six different cow colostrum exosome isolation methods were compared. Method 2 (conventional: differential centrifugation) had the highest purity and greatest amount of microvesicular miRNAs quantified. Identification of selected mRNA and miRNA in microvesicles, unaffected by acidification, and in vitro transfer of RNA from samples. The expression of 6 nanovesicular miRNAs from three biofluids was evaluated, and 2 of them (miR-21 and miR-500) were reported to be stably expressed during different household storage conditions. | [151]|

The terminology used is based on the reference cited, and this division reflects older thinking and is a “pool” of EVs that are responsible for the effects (circRNA, circular RNA; lncRNA, long non-coding RNA; miRNA, micro-RNA; NGS, next-generation sequencing; qPCR, quantitative PCR).

### 4. Stability and Uptake of Milk-Derived EVs

The studies reported in the previous sections described how EVs contain a range of lipids, proteins, and nucleic acids. The stability, i.e., resistance to degradation due to processing or digestion, of milk EVs and cargoes, and how they are taken up by the recipient cells have been studied in cows [159,160,169,177,178,201,204,206–215], humans [167,171,173,202,216,217], goats [218], and buffaloes [205]. These studies are summarised in Table 6.

These studies show that the structure of EVs protects them against harsh conditions, such as low pH, temperature variations, or high concentrations of RNase. This capacity to resist degradation and digestion underpins the study of their potential biological effects, either as nutrient delivery or as drug delivery vehicles.
Table 6. Major findings of studies on the general stability and uptake of mammalian milk-derived EVs.

| Species | Findings | Ref. |
|---------|----------|------|
| **Extracellular vesicle** | Stability and uptake of natural and synthetic EVs loaded with locked nucleic acid anti-sense oligonucleotides in vitro (PHH, NCI-H460 cell line, and hPSC) and in vivo (mice). The impact of industrial processing on milk EVs’ structural integrity and molecular composition. | [216] |
| **Human** | Development of non-invasive fluorescent labelling of EVs in vitro (Caco-2 cell line), demonstrating internalisation and co-localisation of labelled EVs. | [220] |
| **Cow** | Cellular internalisation of EVs in vitro (hPAEC and NRCM). | [109] |
| **Cow** | Time-dependent uptake of colostral miRNA, EV proteins, and isomiRs after feeding in vivo (calves). | [221] |
| **Cow** | Demonstrated that microwaving, but not autoclaving, agitation, or freezing, reduced miR-220c abundance. | [207] |
| **Exosome** | Resistance of exosomes isolated from preterm human milk to in vitro digestion and internalisation in vitro (HIEC). | [169] |
| **Human** | Exosomal protein markers resist degradation by in vitro digestion, pH 4.5, and the uptake of digested and undigested exosomes, based on immunofluorescence imaging of exosomal protein markers in vitro (HIEC). | [171] |
| **Human** | Resistance of miRNA to degradation caused by incubation at 26 °C over 24 h, six freeze–thaw cycles at −20 °C, treatment with RNase A and RNase T1, and incubation at 100 °C for 10 min. | [173] |
| **Human + Cow** | Demonstrated the uptake of RNA ex vivo (macrophages). | [217] |
| **Cow** | Storage at 4 °C substantially reduced the exosome content, especially miRNA, of human milk over time, and the infant formulae tested had no detectable miRNA. Assessed the accumulation and effects of milk exosomes and miRNA cargoes on embryo development in C57BL/6 mice. | [167] |
| **Cow** | Resistance of lncRNA to degradation by in vitro digestion. | [177] |
| **Cow** | Resistance of paclitaxel (chemotherapeutic), encapsulated in these exosomes, to degradation and loss of efficacy from long-term storage at −80 °C for 4 weeks. | [213] |
| **Cow** | Resistance of 5 miRNAs to degradation by an in vitro digestion method and in vitro internalisation of exosomes. | [159] |
| **Cow** | Uptake of exosomes and exosome-encapsulated siRNA (both digested and undigested) in vitro (Caco-2 cell line). Fermentation of milk exosomes with probiotic Streptococcus thermophiles, Lactobacilli, and Bifidobacteria reduces miR-29b and miR-21 abundance and total protein concentration. Challenged the findings from a previous study [160] regarding the dietary transfer of cow milk-derived miRNA in humans. Demonstrated that miR-223 and miR-125b persist in high abundance after simulated in vitro digestion (TNO TIM-1 model). Authors found that exosomes may not be the only carrier of these miRNAs in milk. Uptake and bioavailability of fluorescent-labelled exosomes and their miRNA cargoes via endocytosis in vivo (C57BL/6 mice) and in vitro (HUVEC). Resistance of native miRNA and anticancer compounds encapsulated in these exosomes to degradation from long-term storage at −80 °C for 6 months. Uptake of miRNA in differentiated and undifferentiated THP-1 cells. Uptake and transport of miRNA by endocytosis in vitro (Caco-2 and IEC-6 cell lines). Uptake of miR-29b and miR-200c in a randomised crossover feeding study, in C57BL/6j mice (± miRNA depletion), and human peripheral blood mononuclear cells (PBMCs). Cross-species biodistribution profile of miRNAs in mice and pig model. A novel approach of covalently labelled exosomes with commercial fluorophores in vitro (U87 and B16F10 cell lines) and in vivo (C57BL/6 mice). Uptake, bioavailability, and tissue distribution of radiolabelled (reduced technetium, ⁹⁹ᵐTc (IV)) exosomes using non-invasive single-photon emission computed tomography imaging in Balb/C mice. | [208] | [178] | [201] | [214] | [211] | [210] | [212] | [218] | [223] | [224] |
| **Cow** | Uptake and transport of miRNA by endocytosis in vitro (Caco-2 and IEC-6 cell lines). | [209] |
| **Cow** | Uptake of miR-29b and miR-200c in a randomised crossover feeding study, in C57BL/6j mice (± miRNA depletion), and human peripheral blood mononuclear cells (PBMCs). | [160] |
| **Cow + Pig + Mice** | Cross-species biodistribution profile of miRNAs in mice and pig model. | [223] |
| **Goat + cancer cell lines** | Uptake, bioavailability, and tissue distribution of radiolabelled (reduced technetium, ⁹⁹ᵐTc (IV)) exosomes using non-invasive single-photon emission computed tomography imaging in Balb/C mice. | [218] |
Table 6. Cont.

| Species | Findings | Ref. |
|---------|----------|-----|
| Human   | Presence of immune-related miRNA in human milk, two of which were present in exosomes. miR-21 and miR-181a were resistant to degradation by RNase, pH 1, and freeze–thaw, indicating an extracellular protective mechanism. Pasteurisation and homogenisation, but not 4 °C storage, substantially reduce the abundance of miR-200c and miR29b in four types of milk tested. Somatic cells in the milk accounted for <1% of the abundance of these miRNAs in milk, consistent with these miRNAs packaged in extracellular structures such as EVs. Presence of mRNA and miRNA which were resistant to degradation by RNase, pH 2, incubation at 37 °C, but not Triton X-100, indicating an extracellular protective mechanism. | [202] |
| Cow     | Presence of mRNA and miRNA which were resistant to degradation by RNase, pH 2, incubation at 37 °C, but not Triton X-100, indicating an extracellular protective mechanism. | [215] |
| Cow     | Presence of mRNA and miRNA in both samples. These RNAs were resistant to degradation by pH 2, indicating an extracellular protective mechanism. | [206] |
| Cow     | Demonstrated that 4 °C storage and multiple freeze–thaws reduced the abundance of miR-21 and miR-500. | [204] |
| Buffalo | Demonstrated that 4 °C storage and multiple freeze–thaws reduced the abundance of miR-21 and miR-500. | [205] |

The terminology used is based on the reference cited, and this division reflects older thinking and is a “pool” of EVs that are responsible for the effects (HIEC, human intestinal epithelial crypt-like cell; hPAEC, human pulmonary artery endothelial cell; hPSC, human pluripotent stem cell; HUVEC, human umbilical vein endothelial cell; NRCM, neonatal rat cardiomyocyte; PBMC, peripheral blood mononuclear cell; PHH, primary human hepatocyte).

5. Biological Effects of Milk-Derived EVs

The previous sections indicate that milk-derived EVs may contain bioactive components, which are protected against degradation and digestion. The studies to date that have focused on the biological effects of milk-derived EVs are highlighted in Table 7. The majority of these studies used human or cow milk EVs, and there is a clear knowledge gap regarding whether milk from other species has similar or different effects.

The studies researched the effects of EVs and exosomes on the gut microbiota [201,223,225], on the use of a delivery vehicle [111,159,184,208,213,226–231], in the immune response [60,178,185,203,217,232–237], in diseases such as cancer, [188,189,209,228,231,236,238–247], and in other aspects of cell biology [129,162,248–253]. These studies show that milk-derived EVs can have meaningful biological effects in the model systems used, forming a basis for future research.

Whether these effects in animal and in vitro models translate into humans is unclear. A question remains concerning whether the effects are solely due to EVs and their cargoes or also due to other variable contaminants (e.g., RNA-binding proteins) in the vesicle preparations used in the published studies. The increased rigour and reporting required to comply with the MISEV guidelines are intended to enable more thorough validation of EV research.

Table 7. Major findings of studies on the biological effects of mammalian milk-derived EVs.

| Species | Findings | Ref. |
|---------|----------|-----|
| Human   | Protective effect in vitro (MA-104 and Hep-2 cell lines) against human rotavirus and respiratory syncytial virus. | [254] |
| Human   | In vitro (HFF-1 cell line) antiviral activity against human cytomegalovirus via inhibition of viral replication. | [138] |
| Human   | Antiviral activity against Zika and Usutu in vitro (Vero cell line). | [255] |
| Human   | Coagulant potential of human milk, owing to the presence of tissue factor (TF)-exposing EVs, but not found in cow milk. | [256] |
Table 7. Cont.

| Species | Findings | Ref. |
|---------|----------|-----|
| Human   | Protective effect against experimental-induced NEC in vitro (IEC-6 and FHs 74 Int cell lines) and in vivo (Sprague Dawley pups). Attenuation of inflammatory cytokine expression and nuclear factor (NF)-κB activation in vitro (LPS-stimulated RAW 264.7). | [257] |
| Human + Cow | Promotion of osteogenesis via proliferation and differentiation of osteoblasts in vitro (Saos-2 cell line) and in vivo (Sprague Dawley rats). Improved small intestinal dysfunction in malnutrition C57BL/6j mouse model. Enhancement of curcumin cell uptake and permeability in an intestinal model in vitro (Caco-2 cell line). Osteoprotective effects in vivo (BALB/c and C57BL/6 mice), and decreased the RANKL/OPG ratio in vitro (MLO-Y4 cell line). Induction of phenotypical changes in hPAEC and NRMC cell lines. Modulation of gut microbiota composition, SCFA profiles, and enhancement of intestinal immune regulation by EVs in vitro (RAW 264.7 cell line) and in vivo (C57BL/6j mice). | [258] [259] [260] [261] [249] [109] [225] |
| Cow     | Differential improvements in DSS-induced colitis of two EV subsets via different mechanisms in vivo (C57BL/6j mice). Modulation of agricultural dust-induced lung inflammation by EVs in vitro (MH-S cell line) and in vivo (C57BL/6j mice). Demonstrated sonications effects on EV skeletal muscle biomarkers in vivo (Fischer 344 rats). Biocompatibility and potential use as a non-immunogenic delivery vehicle of EVs in vitro (RAW 264.7) and in vivo (ICR mice). Demonstrated EVs do not cause genotoxicity and contain bioactive TGF-β in vitro (NIH/3T3 cell line), and EVs facilitate differentiation of naive T cells into pathogenic Th17 cells (ex vivo DBA/1J mice). The panel of toxicology studies found differences in toxicological profiles in vitro (HL-60, RAW 264.7, and CHO-K1 cell lines) and ex vivo (human blood). Increased osteocytes number and osteoblast differentiation in vivo (DBA/1j mice), and increased osteoblast differentiation transitioning into osteocytes in vitro (human MSCs). EVs significantly delayed arthritis development in vivo (IL-1Ra−/− and DBA/1j mice). EV uptake demonstrated via ex vivo (mouse ileal cells and splenocytes) and in vitro (RAW 264.7 cells). EVs contain bioactive TGF-β in vitro (NIH/3T3 cell line), and EVs facilitate differentiation of naive T cells into pathogenic Th17 cells (ex vivo DBA/1j mice). | [188] [232] [262] [111] [234] |
| Exosome | Protective effect of both raw and pasteurised exosomes against NEC in vivo (C57BL/6j mice) and ex vivo (neonatal mice intestinal organoids). Demonstrated that miR-148a influenced the proliferation, morphology, and protein expression of transformed cells more than normal cells in vitro (LS123 and CCD841 cell lines). The role of miR-148a was validated using a knockdown model in vitro (293T cell line). Protection against H2O2-induced oxidative stress in NEC in vitro (IEC-6 cell line). Showed uptake of exosomes, increased expression of miR-148a, and decreased expression of DNA-methyltransferase 1 in vitro (CRL-1831, K-562, and LIM1215 cell lines). TGF-β2 influences epithelial–mesenchymal transition in vitro (MCF-7 and MCF 10A cell lines). Inhibition of HIV-1 viral transfer to CD4+ T cells ex vivo (human MDC organoids). The abundance and composition of exosomes vary due to lactation stage, maternal sensitisation, and lifestyle, which influence the regulation of the allergic outcome in the child. The presence of MHC classes I and II, CD63, CD81, and CD86 on exosomes, inhibition of anti-CD3-induced cytokine production, and an increase in Foxp3+ CD4+ CD25+ T regulatory cells ex vivo (human PBMCs). | [239] [189] [240] [244] [235] [247] [60] |
### Table 7. Cont.

| Species          | Findings                                                                 | Ref.   |
|------------------|--------------------------------------------------------------------------|--------|
| Cow              | The loading of miRNA (hsa-miR-148a-3p) as a nanocarrier in vitro (HepG2 and Caco-2 cell lines). | [264]  |
| Cow              | Activation of immune cells ex vivo (human PBMCs) under inflammatory conditions. | [265]  |
| Cow              | Restoration of small intestinal epithelial architecture and barrier function in malnourished C57BL/6j mice. | [266]  |
| Cow              | Exosomes influence macrophage proliferation and protect against cisplatin-induced cytotoxicity in vitro (RAW 264.7 cell line). | [236]  |
| Cow              | Exosomes have cytoprotective and anti-inflammatory activity in ulcerative colitis in vivo (Kindlin 2−/− mice). | [237]  |
| Cow              | Protective effects in vitro (IEC-6 cell line) against oxidative stress. | [267]  |
| Cow              | Osteoporosis prevention in in vitro (MC3T3-E1 and RAW 264.7 cell lines) and in vivo (C57BL/6j mice) models. Additionally, the restoration of gut microbiota affected by osteoarthritis. | [238]  |
| Cow              | Exosomes can be used as an siRNA delivery vehicle in vitro (A549 cell line) and have anti-tumour activity against lung tumour xenografts in vivo (athymic nude mice) and in vitro (MDA-MB-231, MCF7, A549, H1299, PANc-1, Mia PaCa-2, and A2780 cell lines). | [227]  |
| Cow + ASC + Coconut | The use of encapsulated celastrol as a drug delivery vehicle, and anti-tumour activity against lung tumour xenografts in vivo (athymic nude mice, A549 and H1299 cell lines). | [231]  |
| Cow + Mice + Pig | The use of both encapsulated hydrophilic and lipophilic small molecules as a delivery vehicle, with tumour targetability, cross-species tolerance, and enhanced drug efficacy compared to free drugs in vivo (athymic nude mice) and in vitro (A549, H1299, MDA-MB-231, T47D, and Beas-2B cell lines). | [212]  |
| Cow + Yak | Higher growth efficiency in vitro (IEC-6 cell line) under hypoxic conditions when supplemented with yak exosomes rather than cow milk-derived exosomes. | [270]  |
| Buffalo          | Promotion of bacterial growth and alteration of gene expression in vitro (Escherichia coli K-12 MG1655 and Lactobacillus plantarum WCFS1 cultures). | [251]  |
| Buffalo          | Inter-species and intra-species bioavailability and distribution of exosomes in vivo (Balb/c mice). | [223]  |
| Buffalo          | Higher growth efficiency in vitro (IEC-6 cell line) under hypoxic conditions when supplemented with yak exosomes rather than cow milk-derived exosomes. | [270]  |
| Buffalo          | Increased stability, solubility, and bioavailability of digested and undigested EV-encapsulated curcumin in vitro (Caco-2 cell line). | [226]  |
Table 7. Cont.

| Species     | Findings                                                                 | Ref.    |
|-------------|--------------------------------------------------------------------------|---------|
| Camel       | Anticancer effects, via induction of apoptosis, inhibition of oxidative stress, reduced angiogenesis, and metastasis, in vivo (albino rats) and in vitro (MCF7 cell line). | [252]   |
| Rat         | Rat milk-derived exosomes promote intestinal epithelial cell viability, enhance proliferation, and stimulate intestinal stem cell activity in vitro (IEC-18 cell line). | [243]   |
| Pig         | Protective effect against deoxynivalenol (DON)-induced intestinal damage in vivo (Kunming mice) and in vitro (IPEC-J2 cell line). | [271]   |
| Pig         | Protective effects of exosomes against LPS-induced effects in vivo (Kunming mice) and in vitro (IPEC-J2 cell line). | [185]   |
| Pig         | Promotion of digestive tract development, alteration in the expression of proliferation-related genes in vivo (Kunming mice), and altered cell proliferation, proliferation-related gene expression, and miRNA concentration in vitro (IPEC-J2 cell line). | [272]   |
| Pig         | Expression of miRNA during different lactation stages, and a higher uptake of colostrum-derived immune-related miRNA in vivo (piglets). | [181]   |
| Pig + Cow   | Both cow and pig milk exosomes alter serum miRNAs in vivo (piglets), and exosomal miRNA is taken up in vitro (IPEC-J2 cell line). | [162]   |
| Microvesicle/Nanovesicle | Suitability of nanovesicles and encapsulated siRNA as a therapeutic delivery vehicle in vivo (zebrafish) and ex vivo (C57BL/6 splenocytes). | [184]   |
| Cow         | Demonstrated successful uptake of PKH67-labelled microvesicles in vitro (RAW 264.7 cell line). | [203]   |

The terminology used is based on the reference cited, and this division reflects older thinking and is a “pool” of EVs that are responsible for the effects (ASC, adipose-derived stem cell; DSS, dextran sulphate sodium; hPAEC: human pulmonary artery endothelial cell; MDC, monocyte-derived dendritic cell; MSC, mesenchymal stem cell; NEC, necrotising enterocolitis; NRCM, neonatal rate cardiac myocyte; PBMC, peripheral blood mononuclear cell; SCFA, short-chain fatty acid; LPS, lipopolysaccharide).

6. Conclusions

Not all types of milk provide the same nutritional value for inter-species consumption. Species-dependent differences are evident in the macromolecule composition (fat, sugars, etc.), vitamin and mineral content, and how it is digested after consumption [30,273,274]. Furthermore, milk has differences in its molecular composition and conservation of function that influence its specific biological value depending on the species of origin. It is reasonable to propose that EVs in milk from different species may have a differing composition that may affect their nutritional value from an EV-mediated view. Infant formula derived from cow’s milk is still the largest source of non-human infant foods worldwide, but there are areas of the world where cow’s milk is not traditionally consumed.

What nutritional effects that EVs from non-traditional and minority milk may have is poorly understood and represents a substantial gap in our knowledge. We have provided a brief summary of nutritional aspects of mammalian milk and summarised the research on milk-derived EVs of human and common mammalian livestock. We have also discussed research around therapeutic attributes, cargoes of milk-derived EVs, and techniques for working with them.

However, isolating, characterising, and assigning biological effects to milk-derived EVs are challenging due to the highly complex nature of milk as a biofluid. Careful consideration and reporting of standardised methods, i.e., MISEV guidelines, are critical to studies seeking to identify true and meaningful biological effects. The stability and bioavailability of nutrients, combined with their subtle effects (compared to pharmaceuticals), mean that any research on milk EVs needs to be carefully designed to correctly assign their functions in supporting human health.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu13082505/s1, Table S1: Total world milk production quantity (FAOSTAT: 2009 and 2019). Table S2: Raw data extracted from different food composition databases.

Author Contributions: Conceptualisation, S.L.O. and M.J.M.; methodology, S.L.O. and M.J.M.; writing—original draft preparation, S.L.O. and M.J.M.; writing—review and editing, S.L.O., C.B., S.H., A.A.-F., J.A.S.L., J.Z., R.C.A. and M.J.M.; project administration, M.J.M.; funding acquisition, M.J.M. and C.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the New Zealand Ministry of Business, Innovation and Employment Endeavour (Smart Ideas) Fund, grant number C10X1803.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors wish to thank Matthew Barnett and Mallory Crookenden (internal reviewers) for their suggestions that have helped to improve this article.

Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. This review reflects the interpretation of the cited papers by the authors, and readers are strongly encouraged to seek further clarification from the primary references cited.

References
1. Silva, A.R.; Silva, M.M.; Ribeiro, B.D. Health issues and technological aspects of plant-based alternative milk. Food Res. Int. 2020, 131, 108972. [CrossRef] [PubMed]
2. Moatsou, G.; Sakkas, L. Sheep milk components: Focus on nutritional advantages and biofunctional potential. Small Rumin. Res. 2019, 180, 86–99. [CrossRef]
3. Øftedal, O.T. The evolution of lactation in mammalian species. Nestle Nutr. Inst. Workshop Ser. 2020, 94, 1–10. [CrossRef] [PubMed]
4. Chalupa-Krebszak, S.; Long, C.J.; Bohrer, B.M. Nutrient density and nutritional value of milk and plant-based milk alternatives. Int. Dairy J. 2018, 87, 84–92. [CrossRef]
5. Barłowska, J.; Szwajkowska, M.; Litwinczuk, Z.; Król, J. Nutritional Value and Technological Suitability of Milk from Various Animal Species Used for Dairy Production. Compr. Rev. Food Sci. Food Saf. 2011, 10, 291–302. [CrossRef]
6. Evershed, R.P.; Payne, S.; Sherratt, A.G.; Copley, M.S.; Coolidge, J.; Urem-Kotsu, D.; Kotsakis, K.; Özdoğan, M.; Özdoğan, A.E.; Nieuwenhuaye, O.; et al. Earliest date for milk use in the Near East and southeastern Europe linked to cattle herding. Nature 2008, 455, 528–531. [CrossRef]
7. FAOSTAT. Livestock Primary (Total World Milk Production Quantity, 2009 and 2019). Available online: http://www.fao.org/faostat/en/#data/QL (accessed on 7 April 2021).
8. Scholz-Ahrens, K.E.; Ahrens, F.; Barth, C.A. Nutritional and health attributes of milk and milk imitations. Eur. J. Nutr. 2019, 59, 19–34. [CrossRef]
9. Medhammar, E.; Wijesinha-Bettoni, R.; Stadlmayr, B.; Nilsson, E.; Charrodiere, U.R.; Burlingame, B. Composition of milk from minor dairy animals and buffalo breeds: A biodiversity perspective. J. Sci. Food Agric. 2011, 92, 445–474. [CrossRef]
10. Muehlhoff, E.; Bennett, A.; McMahon, D. Milk and Dairy Products in Human Nutrition; Food and Agriculture Organization of the United Nations (FAO): Rome, Italy, 2013.
11. Galley, J.D.; Besner, G.E. The Therapeutic Potential of Breast Milk-Derived Extracellular Vesicles. Nutrients 2020, 12, 745. [CrossRef] [PubMed]
12. Sanwlani, R.; Fonseka, P.; Chitti, S.V.; Mathivanan, S. Milk-Derived Extracellular Vesicles in Inter-Organism, Cross-Species Communication and Drug Delivery. Proteomes 2020, 8, 11. [CrossRef]
13. Melnik, B.C.; Schmitz, G. Exosomes of pasteurized milk: Potential pathogens of Western diseases. J. Transl. Med. 2019, 17, 1–33. [CrossRef]
14. Munir, J.; Lee, M.; Ryu, S. Exosomes in Food: Health Benefits and Clinical Relevance in Diseases. Adv. Nutr. 2019, 11, 687–696. [CrossRef] [PubMed]
15. Zempleni, J. Milk exosomes: Beyond dietary microRNAs. Genes Nutr. 2017, 12, 1–4. [CrossRef]
16. Gomez, C.D.L.T.; Goreham, R.V.; Bec, S., J.J.; Nann, T.; Kissmann, M. “Exosomics”—A Review of Biophysics, Biology and Biochemistry of Exosomes with a Focus on Human Breast Milk. Front. Genet. 2018, 9, 92. [CrossRef] [PubMed]
17. Le Doare, K.; Holder, B.; Bassett, A.; Pananj, P.S. Mother’s Milk: A Purposeful Contribution to the Development of the Infant Microbiota and Immunity. Front. Immunol. 2018, 9, 361. [CrossRef] [PubMed]
18. Foster, B.P.; Balassa, T.; Benen, T.D.; Dominovic, M.; Elmadjian, G.K.; Florova, V.; Fransolet, M.D.; Kestlerova, A.; Kmiecik, G.; Kostadinova, I.A.; et al. Extracellular vesicles in blood, milk and body fluids of the female and male urogenital tract and with special regard to reproduction. *Crit. Rev. Clin. Lab. Sci.* 2016, 53, 379–395. [CrossRef]

19. Souci, S.W.; Fachmann, W.; Kraut, H. *Food Composition and Nutrition Tables*, 8th ed.; MedPharm Scientific Publishers: Stuttgart, Germany, 2015; pp. 1–24, ISBN 978-380-475-072-2.

20. Puwastien, P.; Craven, G. *ASEAN Food Composition Database*, 1st ed.; Institute of Nutrition, Mahidol University: Nakhon Pathom, Thailand, 2014; pp. 24–25, ISBN 974-664-640-7.

21. Musaiger, A.R.O. *Food Composition Tables for Kingdom of Bahrain*; Arab Center for Nutrition: Manama, Bahrain, 2011; pp. 46–49, ISBN 978-999-011-571-0.

22. Vincent, A.; Grande, F.; Compaoré, E.; Ampomah Annor, G.; Addy, P.S.; Aburime, L.C.; Ahmed, D.; Bis Loh, A.M.; Dahdouh Cabia, S.; Deflache, N.; et al. FAO/INFOODS Food Composition Table for Western Africa (2019) User Guide & Condensed Food Composition Table/Table de Composition des Aliments FAO/INFOODS Pour L'Afrique de L'Ouest (2019); FAO: Rome, Italy, 2020; pp. 352–367. ISBN 978-925-132-223-9.

23. Pinchen, H.; Powell, N.; Weiner, D.; Finglas, P. Composition of Foods Integrated Dataset (CoFID). Available online: https://www.gov.uk/government/publications/composition-of-foods-integrated-dataset-cofid (accessed on 7 April 2021).

24. TFDA. Food Composition Database 2019 (New Edition). Available online: https://consumer.fda.gov.tw/Food/TFND.aspx?nodeID=176 (accessed on 7 April 2021).

25. Rhodes, D.G.; Morton, S.; Martin, C.L.; Adler, M.E.; Hymes, M.A.; Garceau, A.O.; Kovalchik, A.; Sattgast, L.H.; Steinfeldt, L.C.; Clemens, J.C.; et al. 2015–2016 *Food and Nutrient Database for Dietary Studies*; U.S. Department of Agriculture, Agricultural Research Service: Beltsville, MD, USA, 2018.

26. Sivakumaran, S. The Concise New Zealand Food Composition Tables, 13th ed.; The New Zealand Institute for Plant and Food Research Limited and Ministry of Health: Auckland, New Zealand, 2018; ISBN 978-047-347-690-8.

27. FSANZ. Australian Food Composition Database. 2017. Available online: https://www.foodstandards.gov.au/science/monitoringnutrients/afcd/Pages/default.aspx (accessed on 7 April 2021).

28. Leung, W.T.W.; Butrum, R.R.; Chang, F.F.H.; Rao, M.N.; Polacchi, W. *Food Composition Table/Table de Composition des Aliments FAO/INFOODS Pour L'Afrique de L'Ouest* (2019); FAO: Rome, Italy, 2020; pp. 801.

29. Frida. Food ID: 1125 Human Milk, Colostrum. Available online: https://frida.fooddata.dk/food/1125?lang=en (accessed on 27 January 2020).

30. Verduci, E.; D’Elios, S.; Cerrato, L.; Palazzo, S.; Martelli, A.; Landi, M.; Trikamjee, T.; Peroni, D.G. Cow’s Milk Substitutes for Children: Nutritional Aspects of Milk from Different Mammalian Species, Special Formula and Plant-Based Beverages. *Nutrients* 2019, 11, 1739. [CrossRef]

31. Andreas, N.J.; Kampmann, B.; Le-Doare, K.M. Human breast milk: A review on its composition and bioactivity. *Early Hum. Dev.* 2015, 91, 629–635. [CrossRef] [PubMed]

32. Fox, P.F.; O’Mahony, J.A. Milk: An Overview. In *Milk Proteins*, 2nd ed.; Singh, H., Boland, M., Thompson, A., Eds.; Academic Press: San Diego, CA, USA, 2014; p. 622.

33. Campbell, J.R.; Marshall, R.T. *The Science of Providing Milk for Man*; McGraw Hill Book Company: New York, NY, USA, 1975; p. 801.

34. Deng, Y.; Misselwitz, B.; Dair, N.; Fox, M. Lactose Intolerance in Adults: Biological Mechanism and Dietary Management. *Nutrients* 2015, 7, 8020–8035. [CrossRef]

35. Vanga, S.K.; Raghavan, V. How well do plant based alternatives fare nutritionally compared to cow’s milk? *J. Food Sci. Technol.* 2017, 55, 10–20. [CrossRef]

36. Luyt, D.; Ball, H.; Makwana, N.; Green, M.R.; Bravin, K.; Nasser, S.M.; Clark, A.T. BSACI guideline for the diagnosis and management of cow’s milk allergy. *Clin. Exp. Allergy* 2014, 44, 642–672. [CrossRef]

37. Boehm, G.; Stahl, B. Oligosaccharides from Milk. *J. Nutr.* 2007, 137, 8475–8495. [CrossRef]

38. Bernard, L.; Bonnet, M.; Delavaud, C.; Delosierre, M.; Ferlay, A.; Fouggère, H.; Graulet, B. Milk Fat Globule in Ruminant: Major and Minor Compounds, Nutritional Regulation and Differences Among Species. *Eur. J. Lipid Sci. Technol.* 2018, 120, 1700039. [CrossRef]

39. Fontecha, J.; Brink, L.; Wu, S.; Pouliot, Y.; Visioli, F.; Jiménez-Flores, R. Sources, Production, and Clinical Treatments of Milk Fat Globule Membrane for Infant Nutrition and Well-Being. *Nutrients* 2020, 12, 1607. [CrossRef]

40. Brink, L.R.; Lönnerdal, B. Milk fat globule membrane: The role of its various components in infant health and development. *J. Nutr. Biochem.* 2020, 85, 108465. [CrossRef]

41. German, J.B.; Dillard, C.J. Composition, Structure and Absorption of Milk Lipids: A Source of Energy, Fat-Soluble Nutrients and Bioactive Molecules. *Crit. Rev. Food Sci. Nutr.* 2006, 46, 57–92. [CrossRef]

42. Zou, X.; Huang, J.; Jin, Q.; Guo, Z.; Liu, Y.; Cheong, L.-Z.; Xu, X.; Wang, X. Lipid Composition Analysis of Milk Fats from Different Mammalian Species: Potential for Use as Human Milk Fat Substitutes. *J. Agric. Food Chem.* 2013, 61, 7070–7080. [CrossRef] [PubMed]

43. Devle, H.; Vetti, I.; Vegarud, G.; Ekeberg, D.; Naess-Andresen, C.F.; Rukke, E.-O. A comparative study of fatty acid profiles in ruminant and non-ruminant milk. *Eur. J. Lipid Sci. Technol.* 2012, 114, 1036–1043. [CrossRef] [PubMed]

44. Pereira, P.C. Milk nutritional composition and its role in human health. *Nutrition* 2014, 30, 619–627. [CrossRef] [PubMed]
45. Hinz, K.; O’Connor, P.M.; Huppertz, T.; Ross, R.; Kelly, A.L. Comparison of the principal proteins in bovine, caprine, buffalo, equine and camel milk. *J. Dairy Res.* 2012, 79, 185–191. [CrossRef]
46. Le, T.T.; Deeth, H.C.; Larsen, L.B. Proteomics of major bovine milk proteins: Novel insights. *Int. Dairy J.* 2017, 67, 2–15. [CrossRef]
47. Truchet, S.; Honvo-Houèu, É. Physiology of milk secretion. *Best Pract. Res. Clin. Endocrinol. Metab.* 2017, 31, 367–384. [CrossRef] [PubMed]
48. Zhang, L.; Boeren, S.; Smits, M.; van Hooijdonk, T.; Vervoort, J.; Hettinga, K. Proteomic study on the stability of proteins in bovine, camel, and caprine milk sera after processing. *Food Res. Int.* 2016, 82, 104–111. [CrossRef]
49. Yang, Y.; Bu, D.; Zhao, X.; Sun, P.; Wang, J.; Zhou, L. Proteomic Analysis of Cow, Yak, Buffalo, Goat and Camel Milk Whey Proteins: Quantitative Differential Expression Patterns. *J. Proteome Res.* 2013, 12, 1660–1667. [CrossRef]
50. Wang, X. Isolation of Extracellular Vesicles from Breast Milk. In *Extracellular Vesicles: Methods and Protocols*; Kuo, W., Jia, S., Walker, J., Eds.; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2017; Volume 1660, pp. 351–353.
51. Lu, J.; Wang, X.; Zhang, W.; Liu, L.; Pang, X.; Zhang, S.; Lv, J. Comparative proteomics of milk fat globule membrane in different species reveals variations in lactation and nutrition. *Food Chem.* 2016, 196, 665–672. [CrossRef] [PubMed]
52. Yang, Y.; Zheng, N.; Wang, W.; Zhao, X.; Zhang, Y.; Han, R.; Ma, L.; Zhao, S.; Li, S.; Guo, T.; et al. N-glycosylation proteome characterization and cross-species comparison of milk fat globule membrane proteins from mammals. *Proteomics* 2016, 16, 2792–2800. [CrossRef] [PubMed]
53. Yang, Y.; Zheng, N.; Zhao, X.; Zhang, Y.; Han, R.; Ma, L.; Zhao, S.; Li, S.; Guo, T.; Wang, J. Proteomic characterization and comparison of mammalian milk fat globule proteomes by iTraq analysis. *J. Proteome* 2015, 116, 34–43. [CrossRef]
54. Spertino, S.; Cipriani, V.; De Angelis, C.; Giuffrida, M.G.; Marsano, F.; Cavaletto, M. Proteome profile and biological activity of caprine, bovine and human milk fat globules. *Mol. Biosyst.* 2012, 8, 967–974. [CrossRef]
55. Roncada, P.; Piras, C.; Soggiu, A.; Turk, R.; Urbanì, A.; Bonizzi, L. Farm animal milk proteomics. *J. Proteom.* 2012, 75, 4259–4274. [CrossRef]
56. Malacarne, M.; Martuzzi, F.; Summer, A.; Mariani, P. Protein and fat composition of mare’s milk: Some nutritional remarks with reference to human and cow’s milk. *Int. Dairy J.* 2002, 12, 869–877. [CrossRef]
57. Graulet, B. Ruminant milk: A source of vitamins in human nutrition. *Anim. Front.* 2014, 4, 24–30. [CrossRef]
58. Guéguen, L.; Pointillart, A. The Bioavailability of Dietary Calcium. *J. Am. Coll. Nutr.* 2000, 19, 1195–1365. [CrossRef] [PubMed]
59. Graulet, B.; Martin, B.; Agabriel, C.; Girard, C.L. Vitamins in Milks. In *Milk and Dairy Products in Human Nutrition*, Beghein, E.; et al. [Eds.]; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2017; Volume 1660, pp. 351–353.
60. Zempleni, J.; Baier, S.R.; Howard, K.M.; Cui, J. Gene regulation by dietary microRNAs. *Can. J. Physiol. Pharmacol.* 2012, 90, 228–232. [CrossRef] [PubMed]
61. Zempleni, J.; Aguilar-Lozano, A.; Sadri, M.; Sukreet, S.; Manca, S.; Wu, D.; Zhou, F.; Mutai, E. Biological Activities of Extracellular Vesicles and Their Cargos from Bovine and Human Milk in Humans and Implications for Infants. *J. Nutr.* 2016, 147, 3–10. [CrossRef]
62. Zempleni, J.; Auclair, J.; Howard, K.M.; Cui, J. Gene regulation by dietary microRNAs. *Can. J. Physiol. Pharmacol.* 2015, 93, 1097–1102. [CrossRef] [PubMed]
63. Zempleni, J.; Baier, S.R.; Howard, K.M.; Cui, J. Gene regulation by dietary microRNAs. *Can. J. Physiol. Pharmacol.* 2015, 93, 1097–1102. [CrossRef] [PubMed]
64. Zempleni, J.; Baier, S.R.; Howard, K.M.; Cui, J. Gene regulation by dietary microRNAs. *Can. J. Physiol. Pharmacol.* 2015, 93, 1097–1102. [CrossRef] [PubMed]
65. Zempleni, J.; Baier, S.R.; Howard, K.M.; Cui, J. Gene regulation by dietary microRNAs. *Can. J. Physiol. Pharmacol.* 2015, 93, 1097–1102. [CrossRef] [PubMed]
66. Théry, C.; Witwer, K.W.; Aikawa, E.; Alcaraz, M.J.; Anderson, J.D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G.K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J. Extracell. Vesicles* 2018, 7, 1535750. [CrossRef] [PubMed]
67. Witwer, K.W.; Soekmadji, C.; Hill, A.F.; Wauben, M.H.; Buzás, E.I.; Di Vizio, D.; Falcon-Perez, J.M.; Gardiner, C.; Hochberg, F.; Kurochkin, I.V.; et al. Updating the MISEV minimal requirements for extracellular vesicle studies: Building bridges to reproducibility. *J. Extracell. Vesicles* 2017, 6, 1396823. [CrossRef]
68. Lötvall, J.; Hill, A.; Hochberg, F.; Buzás, E.I.; Di Vizio, D.; Gardiner, C.; Gho, Y.S.; Kurochkin, I.V.; Mathivanan, S.; Quesenberry, P.; et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* 2014, 3, 26913. [CrossRef] [PubMed]
69. Roux, Q.; van Deun, J.; Dedeyne, S.; Hendrix, A. The EV-TRACK summary add-on: Integration of experimental information in databases to ensure comprehensive interpretation of biological knowledge on extracellular vesicles. *J. Extracell. Vesicles* 2020, 9, 1699367. [CrossRef]
70. Van Deun, J.; EV-TRACK Consortium; Mestdagh, P.; Agostinis, P.; Akay, Ö.; Anand, S.; Anckaert, J.; Martinez, Z.A.; Baetens, T.; Beghein, E.; et al. EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research. *Nat. Methods* 2017, 14, 228–232. [CrossRef]
99. Heinemann, M.L.; Vykonlak, J. Sequential Filtration: A Gentle Method for the Isolation of Functional Extracellular Vesicles. In *Extracellular Vesicles: Methods and Protocols*, 1st ed.; Kuo, W.P., Jia, S., Walker, J., Eds.; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2017; Volume 1660, pp. 33–41, ISBN 978-149-397-253-1.

100. Meng, Y.; Asghari, M.; Aslan, M.K.; Yilmaz, A.; Mateescu, B.; Stavrakis, S.; Demello, A.J. Microfluidics for extracellular vesicle separation and mimetic synthesis: Recent advances and future perspectives. *Chem. Eng. J.* 2021, 404, 126110. [CrossRef]

101. Vogel, R.; Savage, J.; Muzard, J.; Della Camera, G.; Vella, G.; Law, A.; Marchioni, M.; Mehri, D.; Geiss, O.; Peacock, B.; et al. Measuring particle concentration of multimodal synthetic reference materials and extracellular vesicles with orthogonal techniques: Who is up to the challenge? *J. Extracell. Vesicles* 2021, 10, e12052. [CrossRef]

102. Shao, H.; Im, H.; Castro, C.M.; Breakefield, X.; Weissleder, R.; Lee, H. New Technologies for Analysis of Extracellular Vesicles. *Chem. Rev.* 2018, 118, 1917–1950. [CrossRef]

103. Shpavocitch, V.; Hergenröder, R. Optical and surface plasmonic approaches to characterize extracellular vesicles: A review. *Anal. Chim. Acta* 2018, 1005, 1–15. [CrossRef]

104. Chia, B.S.; Low, Y.P.; Wang, Q.; Li, P.; Gao, Z. Advances in exosome quantification techniques. *TrAC Trends Anal. Chem.* 2017, 86, 93–106. [CrossRef]

105. Bickmore, D.C.; Miklavcic, J.J. Characterization of Extracellular Vesicles Isolated from Human Milk Using a Precipitation-Based Method. *Front. Nutr.* 2020, 7, 22. [CrossRef] [PubMed]

106. Bickmore, D.C. *Elucidating the Relation between Human Milk Fatty Acids, Extracellular Vesicles, and Infant Developmental Outcomes in the First Year of Life;* Chapman University: Orange, CA, USA, 2020.

107. Zonneveld, M.; Brisson, A.R.; van Herwijnen, M.; Tan, S.; Van De Lest, C.H.A.; Redegeld, F.A.; Garssen, J.; Wauben, M.; Hoen, E.N.M.N. Recovery of extracellular vesicles from human breast milk is influenced by sample collection and vesicle isolation procedures. *J. Extracell. Vesicles* 2014, 3. [CrossRef] [PubMed]

108. Vaswani, K.; Koh, Y.Q.; Almughlliq, F.; Peiris, H.; Mitchell, M.D. A method for the isolation and enrichment of purified bovine extracellular vesicles from bovine milk. *PLoS ONE* 2019, 14, e0222613. [CrossRef]

109. Somiya, M.; Yoshioka, Y.; Ochiya, T. Biocompatibility of highly purified bovine milk-derived extracellular vesicles. *J. Extracell. Vesicles* 2018, 7, 144032. [CrossRef]

110. Polliott, G.; Brito, A.; Gardiner, C.; Lawson, C. A Comparison of Different Methodologies for the Measurement of Extracellular Vesicles and Milk-derived Particles in Raw Milk from Cows. *Biomark. Insights* 2016, 11, 147–155. [CrossRef]

111. Jackson, K.; Powell, R.R.; Bruce, T.F.; Marcus, R.K. Solid-phase extraction of exosomes from diverse matrices via a polyester capillary-channeled polymer (C-CP) fiber stationary phase in a spin-down tip format. *Anal. Bioanal. Chem.* 2020, 412, 4713–4724. [CrossRef]

112. Yamauchi, M.; Shimizu, K.; Yamauchi, M.; Takase, H.; Ugawa, S.; Okada, A.; Inoshima, Y. Acidification effects on isolation of extracellular vesicles from bovine milk. *PLoS ONE* 2019, 14, e0222613. [CrossRef]

113. Pollott, G.; Brito, A.; Gardiner, C.; Lawson, C. A Comparison of Different Methodologies for the Measurement of Extracellular Vesicles and Milk-derived Particles in Raw Milk from Cows. *Biomark. Insights* 2016, 11, 147–155. [CrossRef]

114. Yamauchi, M.; Ishikawa, H.; Takase, H.; Ugawa, S.; Okada, A.; Inoshima, Y. Efficient method for isolation of exosomes from raw bovine milk. *Drug Dev. Ind. Pharm.* 2018, 45, 359–364. [CrossRef]

115. Vaswani, K.; Koh, Y.Q.; Almughlliq, F.; Peiris, H.; Mitchell, M.D. A method for the isolation and enrichment of purified bovine milk exosomes. *Reprod. Biol. Med.* 2017, 17, 341–348. [CrossRef] [PubMed]

116. Yamada, T.; Inoshima, Y.; Matsuda, T.; Ishiguro, N. Comparison of Methods for Isolating Exosomes from Bovine Milk. *J. Vet. Med. Sci.* 2012, 74, 1523–1525. [CrossRef] [PubMed]

117. Vaswani, K.; Mitchell, M.; Holland, O.; Koh, Y.Q.; Hill, R.J.; Harb, T.; Davies, P.S.W.; Peiris, H. A Method for the Isolation of Exosomes from Human and Bovine Milk. *J. Nutr. Metab.* 2019, 2019, 1–6. [CrossRef] [PubMed]

118. Blans, K.; Hansen, M.S.; Sørensen, L.V.; Hvam, M.L.; Howard, K.A.; Moeller, A.; Wiking, L.; Larsen, L.B.; Rasmussen, J.T. Pellet-free isolation of human and bovine milk extracellular vesicles by size-exclusion chromatography. *J. Extracell. Vesicles* 2017, 6, 1294340. [CrossRef] [PubMed]

119. Choi, D.-S.; Kim, D.-K.; Kim, Y.-K.; Gho, Y.S. Proteomics of extracellular vesicles: Exosomes and ectosomes. *Mass Spectrom. Rev.* 2014, 34, 474–490. [CrossRef] [PubMed]

120. Kreimer, S.; Belov, A.M.; Ghirani, I.; Murthy, S.K.; Frank, D.A.; Ivanov, A.R. Mass-Spectrometry-Based Molecular Characterization of Extracellular Vesicles: Lipidomics and Proteomics. *J. Proteome Res.* 2015, 14, 2367–2384. [CrossRef] [PubMed]

121. Pocsfalvi, G.; Stanly, C.; Fiume, I.; Vékey, K. Chromatography and its hyphenation to mass spectrometry for extracellular vesicle analysis. *J. Chromatogr. A* 2016, 1439, 26–41. [CrossRef] [PubMed]

122. Pocsfalvi, G.; Stanly, C.; Vílasi, A.; Fiume, I.; Capasso, G.; Turiáč, L.; Buzas, E.I.; Vékey, K. Mass spectrometry of extracellular vesicles. *Mass Spectrom. Rev.* 2015, 35, 3–21. [CrossRef] [PubMed]

123. Schmidt, A.; Forne, I.; Imhof, A. Bioinformatic analysis of proteomics data. *BMC Syst. Biol.* 2014, 8. [CrossRef] [PubMed]
125. Mecocci, S.; Gevi, F.; Pietrucci, D.; Cavinato, L.; Luly, F.R.; Pascucci, L.; Petrini, S.; Ascenzioni, F.; Zolla, L.; Chillemi, G.; et al.

126. Rahaman, M.; Badr, Y.; Kamatari, Y.O.; Kitamura, Y.; Shimizu, K.; Okada, A.; Inoshima, Y. Data on proteomic analysis of milk.

127. Van Niel, G.; Raposo, G.; Candalh, C.; Boussac, M.; Hershberg, R.; Cerf-Bensussan, N.; Heyman, M. Intestinal epithelial cells secrete exosome-like vesicles. *Gastroenterology* 2001, 121, 337–349. [CrossRef] [PubMed]

128. Reinhartd, T.A.; Lippolis, J.; Nonnecke, B.J.; Sacco, R.E. Bovine milk exosome proteome. *J. Proteom.* 2012, 75, 1486–1492. [CrossRef]

129. Chen, T.; Xi, Q.-Y.; Sun, J.-J.; Ye, R.-S.; Cheng, X.; Sun, R.-P.; Wang, S.-B.; Shu, G.; Wang, L.-N.; Zhu, X.-T.; et al. Revelation of mRNAs and proteins in porcine milk by transcriptomic and proteomic analysis. *BMC Vet. Res.* 2017, 13, 1–14. [CrossRef] [PubMed]

130. Van Herwijnen, M.; Zonneveld, M.; Goerdalay, S.; Nolte, E.N.; Garssen, J.; Stahl, B.; Altelar, A.M.; Redegeld, F.A.; Wauben, M.H. Comprehensive Proteomic Analysis of Human Milk-derived Extracellular Vesicles Unveils a Novel Functional Proteome Distinct from Other Milk Components. *Mol. Cell. Proteom.* 2016, 15, 3412–3423. [CrossRef]

131. Brown, B.A.; Zeng, X.; Todd, A.R.; Barnes, L.F.; Winstone, J.M.A.; Trinidad, J.C.; Novotny, M.V.; Jarrold, M.F.; Clemmer, D.E. Charge Detection Mass Spectrometry Measurements of Exosomes and other Extracellular Particles Enriched from Bovine Milk. *Anal. Chem.* 2020, 92, 3285–3292. [CrossRef]

132. Benmoussa, A.; Gotti, C.; Bourassa, S.; Gilbert, C.; Provost, P. Identification of protein markers for extracellular vesicle (EV) subsets in cow’s milk. *J. Proteom.* 2019, 192, 78–88. [CrossRef]

133. Benmoussa, A.; Ly, S.; Shan, S.T.; Laugier, J.; Boilard, E.; Gilbert, C.; Provost, P. A subset of extracellular vesicles carries the bulk of microRNAs in commercial dairy cow’s milk. *J. Extracell. Vesicles* 2017, 6, 140197. [CrossRef] [PubMed]

134. Ryskaïeva, A.; Krupova, Z.; Henry, C.; Faye, B.; Konuspayeva, G.; Martin, P. Comprehensive proteomic analysis of camel milk-derived extracellular vesicles. *Int. J. Biol. Chem.* 2019, 12, 93–104. [CrossRef]

135. Wang, X.; Yan, X.; Zhang, L.; Cai, J.; Zhou, Y.; Liu, H.; Hu, Y.; Chen, W.; Xu, S.; Liu, P.; et al. Identification and Peptidomic Profiling of Exosomes in Preterm Human Milk: Insights into Necrotizing Enterocolitis Prevention. *Mol. Nutr. Food Res.* 2019, e1801247. [CrossRef]

136. Samuel, M.; Chisanga, D.; Liem, M.; Keerthikumar, S.; Anand, S.; Ang, C.-S.; Adda, C.; Versteegen, E.; Jois, M.; Mathivanan, S. Bovine milk-derived exosomes from colostrum are enriched with proteins implicated in immune response and growth. *Sci. Rep.* 2017, 7, 5933. [CrossRef] [PubMed]

137. Koh, Y.Q.; Peiris, H.N.; Vaswani, K.; Meier, S.; Burke, C.R.; Macdonald, K.A.; Roche, J.R.; Arachchige, B.J.; Reed, S.; et al. Characterization of exosomes from body fluids of dairy cows. *J. Anim. Sci.* 2015, 93, 3893–3904. [CrossRef]

138. Donalisio, M.; Cirrincione, S.; Rittà, M.; Lamberti, C.; Civrà, A.; Francese, R.; Tonetto, P.; Sottemano, S.; Manfredi, M.; Lorenzato, A.; et al. Extracellular Vesicles in Human Preterm Colostrum Inhibit Infection by Human Cytomegalovirus In Vitro. *Microorganisms* 2020, 8, 1087. [CrossRef] [PubMed]

139. Rahman, M.; Takashima, S.; Kamatari, Y.O.; Badr, Y.; Kitamura, Y.; Shimizu, K.; Okada, A.; Inoshima, Y. Proteomic profiling of milk small extracellular vesicles from bovine leukemia virus-infected cattle. *Sci. Rep.* 2021, 11, 1–11. [CrossRef]

140. Rahman, M.; Badr, Y.; Kamatari, Y.O.; Kitamura, Y.; Shimizu, K.; Okada, A.; Inoshima, Y. Data on proteomic analysis of milk extracellular vesicles from bovine leukemia virus-infected cattle. *Data Brief* 2020, 33, 106510. [CrossRef] [PubMed]

141. Meccoci, S.; Gifi, F.; Pietrucci, D.; Cavinato, L.; Luly, F.R.; Pascucci, L.; Petrini, S.; Ascenzi, F.; Zolla, L.; Chillemi, G.; et al. Anti-Inflammatory Potential of Cow, Donkey and Goat Milk Extracellular Vesicles as Revealed by Metabolomic Profile. *Nutrients* 2020, 12, 2908. [CrossRef]

142. Yang, M.; Song, D.; Cao, X.; Wu, R.; Liu, B.; Ye, W.; Wu, J.; Yue, X. Comparative proteomic analysis of milk-derived exosomes in human and bovine colostrum and mature milk samples by iTRAQ-coupled LC-MS/MS. *Food Res. Int.* 2017, 92, 17–25. [CrossRef]

143. Reinhartd, T.A.; Sacco, R.E.; Nonnecke, B.J.; Lippolis, J. Bovine milk proteome: Quantitative changes in normal milk exosomes, milk fat globule membranes and whey proteomes resulting from Staphylococcus aureus mastitis. *J. Proteom.* 2013, 82, 141–154. [CrossRef]

144. Sedykh, S.E.; Purvinish, L.V.; Monogarov, A.S.; Burkova, E.E.; Grigor’Eva, A.E.; Bulgakov, D.; Dmitrenok, P.S.; Vlassov, V.V.; Ryabchikova, E.I.; Nevinsky, G.A. Purified horse milk exosomes contain an unpredictable small number of major proteins. *Biochim. Open* 2017, 4, 61–72. [CrossRef]

145. Skotland, T.; Hessvik, N.P.; Sandvig, K.; Llorente, A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. *J. Lipid Res.* 2019, 60, 9–18. [CrossRef] [PubMed]

146. Robbins, P.D.; Morelli, A.E. Regulation of immune responses by extracellular vesicles. *Nat. Rev. Immunol.* 2014, 14, 195–208. [CrossRef] [PubMed]

147. Rustam, Y.H.; Reid, G.E. Analytical Challenges and Recent Advances in Mass Spectrometry Based Lipidomics. *Anal. Chem.* 2017, 90, 374–397. [CrossRef] [PubMed]

148. Wood, P.L.; Cebak, J.E. Lipidomics biomarker studies: Errors, limitations, and the future. *Biochem. Biophys. Res. Commun.* 2018, 504, 569–575. [CrossRef]
149. Subra, C.; Lauлагnier, K.; Perret, B.; Record, M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. *Biochimie* 2007, 89, 205–212. [CrossRef]

150. Skotland, T.; Sagini, K.; Sandvig, K.; Llorente, A. An emerging focus on lipids in extracellular vesicles. *Adv. Drug Deliv. Rev.* 2020, 159, 308–321. [CrossRef]

151. Yassin, A.M.; Hamid, M.I.A.; Farid, O.A.; Amer, H.; Warda, M. Dromedary milk exosomes as mammamy transcriptome nano-vehicle: Their isolation, vesicular and phospholipidic characterizations. *J. Adv. Res.* 2016, 7, 749–756. [CrossRef]

152. Castro-Gómez, P.; Garcia-Serrano, A.; Visioli, F.; Fontecha, J. Relevance of dietary glycerophospholipids and sphingolipids to human health. *Prostaglandins Leukot. Essent. Fat. Acids* 2015, 101, 41–51. [CrossRef] [PubMed]

153. Demmelmair, H.; Koletzko, B. Lipids in human milk. *Best Pract. Res. Clin. Endocrinol. Metab.* 2018, 32, 57–68. [CrossRef] [PubMed]

154. Koletzko, B.; Rodriguez-Palmero, M.; Demmelmair, H.; Fidler, N.; Jensen, R.; Sauerwald, T. Physiological aspects of human milk lipids. *Early Hum. Dev.* 2001, 65, S3–S18. [CrossRef]

155. Koletzko, B. Human milk lipids. *Ann. Nutr. Metab.* 2016, 69, 28–40. [CrossRef]

156. Ali, A.H.; Zou, X.; Abed, S.M.; Korma, S.A.; Jin, Q.; Wang, X. Natural phospholipids: Occurrence, biosynthesis, separation, identification, and beneficial health aspects. *Crit. Rev. Food Sci. Nutr.* 2017, 59, 253–275. [CrossRef]

157. Boilard, E. Thematic Review Series: Exosomes and Microvesicles: Lipids as Key Components of their Biogenesis and Functions Extracellular vesicles and their content in bioactive lipid mediators: More than a stack of microRNA. *J. Lipid Res.* 2018, 59, 2037–2046. [CrossRef]

158. Cai, M.; He, H.; Jia, X.; Chen, S.; Wang, J.; Shi, Y.; Liu, B.; Xiao, W.; Lai, S. Genome-wide microRNA profiling of bovine milk-derived exosomes infected with *Staphylococcus aureus*. *Cell Stress Chaperones* 2018, 23, 663–672. [CrossRef] [PubMed]

159. Rani, P.; Vashisht, M.; Golla, N.; Sandilaya, S.; Oteru, S.K.; Singh, D. Milk miRNAs encapsulated in exosomes are stable to human digestion and permeable to intestinal barrier in vitro. *J. Funct. Foods* 2017, 34, 431–439. [CrossRef]

160. Baier, S.R.; Nguyen, C.; Xie, E.; Wood, J.R.; Zempleni, J. MicroRNAs Are Absorbed in Biologically Meaningful Amounts from Nutritionally Relevant Doses of Cow Milk and Affect Gene Expression in Peripheral Blood Mononuclear Cells, HEK-293 Kidney Cell Cultures, and Mouse Livers. *J. Nutr. 2014, 144, 1495–1500. [CrossRef]

161. Wang, L.; Sadri, M.; Giraud, D.; Zempleni, J. RNAse H2-Dependent Polymerase Chain Reaction and Elimination of Confounders in Sample Collection, Storage, and Analysis Strengthen Evidence That microRNAs in Bovine Milk Are Bioavailable in Humans. *J. Nutr. 2018, 148, 153–159. [CrossRef] [PubMed]

162. Liu, D.; Chen, T.; Xie, M.; Li, M.; Zeng, B.; Sun, R.; Zhu, Y.; Ye, D.; Wu, J.; Sun, J.; et al. Oral Administration of Bovine and Porcine Milk Exosome Alter miRNAs Profiles in Piglet Serum. *Sci. Rep.* 2020, 10, 6983. [CrossRef] [PubMed]

163. Bennoussa, A.; Provost, P. Milk MicroRNAs in Health and Disease. *Compr. Rev. Food Sci. Food Saf.* 2019, 18, 703–722. [CrossRef]

164. Tomé-Carneiro, J.; Fernández-Alonso, N.; Tomás-Zapico, C.; Visioli, F.; Iglesias-Gutierrez, E.; Dávalos, A. Breast milk microRNAs harsh journey towards potential effects in infant development and maturation. Lipid encapsulation can help. *Pharmaco. Res. 2018, 132, 21–32. [CrossRef]

165. Cintio, M.; Polacchini, G.; Scarsella, E.; Montanari, T.; Stefanon, B.; Colitti, M. MicroRNA Milk Exosomes: From Cellular Regulator to Genomic Marker. *Animals 2020, 10, 1126. [CrossRef] [PubMed]

166. Colitti, M.; Sgorlon, S.; Stefanon, B. Exosome cargo in milk as a potential marker of cow health. *J. Dairy Res. 2020, 87, 79–83. [CrossRef]

167. Leiferman, A.; Shu, J.; Upadhyaya, B.; Cui, J.; Zempleni, J. Storage of Extracellular Vesicles in Human Milk, and MicroRNA Profiles in Human Milk Exosomes and Infant Formulas. *J. Pediatr. Gastroenterol. Nutr.* 2019, 69, 235–238. [CrossRef] [PubMed]

168. Mirza, A.H.; Kaur, S.; Nielsen, L.B.; Sterling, J.; Yarani, R.; Roursgaard, M.; Mathiesen, E.R.; Damian, P.; Svaare, J.; Mortensen, H.B.; et al. Breast Milk-Derived Extracellular Vesicles Enriched in Exosomes from Mothers with Type 1 Diabetes Contain Aberrant Levels of microRNA. *Front. Immunol.* 2019, 144, 2543. [CrossRef]

169. Kahn, S.; Liao, Y.; Du, X.; Xu, W.; Li, J.; Lönnerved, B. Exosomal MicroRNAs in Milk from Mothers Delivering Preterm Infants Survive In Vitro Digestion and Are Taken Up by Human Intestinal Cells. *Mol. Nutr. Food Res.* 2018, 62, e1701050. [CrossRef]

170. Van Herwijnen, M.J.C.; Driedonks, T.; Snoek, B.; Kroon, A.M.T.; Kleinjan, M.; Jorritsma, R.; Pieterse, C.; Hoen, E.N.M.N.; Wauben, M. Abundantly Present miRNAs in Milk-Derived Extracellular Vesicles Are Conserved Between Mammals. *Front. Nutr. 2018, 5, 81. [CrossRef]

171. Liao, Y.; Du, X.; Yalin, L.; Lönnerved, B. Human milk exosomes and their microRNAs survive digestion in vitro and are taken up by human intestinal cells. *Mol. Nutr. Food Res.* 2017, 61. [CrossRef]

172. Simpson, M.R.; Brede, G.; Johansen, J.; Johnsen, R.; Storro, O.; Sætrom, P.; Øien, T. Human Breast Milk miRNA, Maternal Probiotic Supplementation and Atopic Dermatitis in Offspring. *PLoS ONE* 2015, 10, e0143496. [CrossRef]

173. Zhou, Q.; Li, M.; Wang, X.; Li, Q.; Wang, T.; Zhou, X.; Wang, X.; Gao, X.; Li, X. Immune-related MicroRNAs are Abundant in Breast Milk Exosomes. *Int. J. Biol. Sci.* 2012, 8, 118–123. [CrossRef]

174. Bennoussa, A.; Laugier, J.; Beauparlant, C.J.; Lambert, M.; Droit, A.; Provost, P. Complexity of the microRNA transcriptome of cow milk and milk-derived extracellular vesicles isolated via differential ultracentrifugation. *J. Dairy Sci.* 2020, 103, 16–29. [CrossRef]

175. Quan, S.-Y.; Nan, X.-M.; Wang, K.; Zhao, Y.-G.; Jiang, L.-S.; Yao, J.-H.; Xiong, B.-H. Replacement of forage fiber with non-forage fiber sources in dairy cow diets changes milk extracellular vesicle-miRNA expression. *Food Funct.* 2020, 11, 2154–2162. [CrossRef]
Ma, S.; Tong, C.; Ibeagha-Awemu, E.M.; Zhao, X. Identification and characterization of differentially expressed exosomal microRNAs in bovine milk infected with Staphylococcus aureus. *BMC Genom.* 2019, 20, 1–13. [CrossRef]

Zeng, B.; Chen, T.; Xie, M.-Y.; Luo, J.-Y.; He, J.-J.; Xi, Q.-Y.; Sun, J.-J.; Zhang, Y.-L. Exploration of long noncoding RNA in bovine milk exosomes and their stability during digestion in vitro. *J. Dairy Sci.* 2019, 102, 6726–6737. [CrossRef]

Izumi, H.; Tsuda, M.; Sato, Y.; Kosaka, N.; Ochiya, T.; Iwamoto, H.; Namba, K.; Takeda, Y. Bovine milk exosomes contain microRNA and mRNA and are taken up by human macrophages. *J. Dairy Sci.* 2015, 98, 2920–2933. [CrossRef] [PubMed]

Sun, J.; Aswath, K.; Schroeder, S.G.; Lippolis, J.D.; et al. MicroRNA expression profiles of bovine milk exosomes in response to Staphylococcus aureus infection. *BMC Genom.* 2015, 16, 1–10. [CrossRef]

Chen, T.; Xi, Q.-Y.; Ye, R.-S.; Cheng, X.; Qi, Q.-E.; Wang, S.-B.; Shu, G.; Wang, L.-N.; Zhu, X.-T.; Jiang, Q.-Y.; et al. Exploration of microRNA in porcine milk exosomes. *BMC Genom.* 2014, 15, 100. [CrossRef]

Gu, Y.; Li, M.; Wang, T.; Liang, Y.; Zhong, Z.; Wang, X.; Zhou, Q.; Chen, L.; Lang, Q.; He, Z.; et al. Lactation-Related MicroRNA Expression Profiles of Porcine Breast Milk Exosomes. *PLoS ONE* 2012, 7, e43691. [CrossRef]

Quan, S.; Nan, X.; Wang, K.; Jiang, L.; Yao, J.; Xiong, B. Characterization of Sheep Milk Extracellular Vesicle-miRNA by Sequencing and Comparison with Cow Milk. *Animals* 2020, 10, 331. [CrossRef]

Chen, Z.; Xie, Y.; Luo, J.; Chen, T.; Xi, Q.; Zhang, Y.; Sun, J. Milk exosome-derived miRNAs from water buffalo are implicated in immune response and metabolism process. *BMC Vet. Res.* 2020, 16, 1–5. [CrossRef]

Matsuda, A.; Moirangthem, A.; Angom, R.S.; Ishiguro, K.; Driscoll, J.; Yan, I.K.; Mukhopadhyay, D.; Patel, T. Safety of bovine milk derived extracellular vesicles used for delivery of RNA therapeutics in zebrafish and mice. *J. Appl. Toxicol.* 2019, 40, 706–718. [CrossRef]

Xie, M.-Y.; Hou, L.-J.; Sun, J.-J.; Zeng, B.; Xi, Q.-Y.; Luo, J.-Y.; Chen, T.; Zhang, Y.-L. Porcine Milk Exosome MiRNAs Attenuate LPS-Induced Apoptosis through Inhibiting TLR4/NF-κB and p53 Pathways in Intestinal Epithelial Cells. *J. Agric. Food Chem.* 2019, 67, 9477–9491. [CrossRef]

Matsuda, A.; Patel, T. Milk-derived Extracellular Vesicles for Therapeutic Delivery of Small Interfering RNAs. In *Extracellular RNA: Methods and Protocols*, 1st ed.; Patel, T., Walker, J., Eds.; Methods in Molecular Biology; Humana Press: New York, NY, USA, 2018; Volume 1740, pp. 187–197, ISBN 978-149-397-652-2. [CrossRef]

Ishikawa, H.; Rahman, M.; Yamauchi, M.; Wakihara, Y.; Kamatari, Y.O.; Shimizu, K.; Okada, A.; Inoshima, Y. mRNA Profile in Milk Extracellular Vesicles from Bovine Leukemia Virus-Infected Cattle. *Viruses* 2020, 12, 669. [CrossRef]

Benmoussa, A.; Diaiolo, I.; Salem, M.; Michel, S.; Gilbert, C.; Sévigny, J.; Provost, P. Concentrates of two subsets of extracellular vesicles from cow’s milk modulate symptoms and inflammation in experimental colitis. *Sci. Rep.* 2019, 9, 1–16. [CrossRef]

Reif, S.; Shiff, Y.E.; Golan-Gerstl, R.; Reif, S.; Shiff, Y.E.; Golan-Gerstl, R. Milk-derived exosomes (MDEs) have a different biological effect on normal fetal colon epithelial cells compared to colon tumor cells in a miRNA-dependent manner. *J. Transl. Med.* 2019, 17, 325. [CrossRef]

Melnik, B.C.; Schmitz, G. MicroRNAs: Milk’s epigenetic regulators. *Best Pract. Res. Clin. Endocrinol. Metab.* 2017, 31, 427–442. [CrossRef]

Melnik, B.C.; Kakulas, F.; Geddes, D.T.; Hartmann, P.E.; John, S.M.; Carrera-Bastos, P.; Cordain, L.; Schmitz, G. Milk miRNAs: Simple nutrients or systemic functional regulators? *Nutr. Metab.* 2016, 13, 42. [CrossRef] [PubMed]

Melnik, B.C. Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Transplantation. *Int. J. Mol. Sci.* 2015, 16, 17048–17078. [CrossRef] [PubMed]

Melnik, B.C.; John, S.M.; Schmitz, G. Milk: An exosomal microRNA transmitter promoting thymic regulatory T cell maturation preventing the development of atopy? *J. Transl. Med.* 2014, 12, 43. [CrossRef] [PubMed]

Melnik, B.C.; John, S.M.; Schmitz, G. Milk is not just food but most likely a genetic transfection system activating mTORC1 signaling for postnatal growth. *Nutr.* 2013, 12, 103. [CrossRef] [PubMed]

Kupsco, A.; Prada, D.; Valvi, D.; Hu, L.; Petersen, M.S.; Coull, B.; Grandjean, P.; Weihe, P.; Baccarelli, A.A. Human milk extracellular vesicle miRNA expression and associations with maternal characteristics in a population-based cohort from the Faroe Islands. *Sci. Rep.* 2021, 11, 5840. [CrossRef] [PubMed]

Karlsson, O.; Rodosthenous, R.; Jara, C.; Brennan, K.J.; Wright, R.; Baccarelli, A.A.; Wright, R.J. Detection of long non-coding RNAs in human breastmilk extracellular vesicles: Implications for early child development. *Epigenetics* 2016, 11, 721–729. [CrossRef]

Ma, S.; Niu, M.; Hoo, Z.; Liu, M.; Tong, C.; Zhao, X. Selective packaged circular RNAs in milk extracellular vesicles during Staphylococcus aureus infection may have potential against bacterial infection. *RNA Biol.* 2020, 18, 818–831. [CrossRef] [PubMed]

Lukasik, A.; Zielenkiewicz, P. In Silico Identification of Plant miRNAs in Mammalian Breast Milk Exosomes—A Small Step Forward? *PLoS ONE* 2014, 9, e99963. [CrossRef] [PubMed]

Mutai, E.; Ramer-Tait, A.E.; Zempleni, J. MicroRNAs in bovine milk exosomes are bioavailable in humans but do not elicit a robust pro-inflammatory cytokine response. *ExRNA* 2020, 2. [CrossRef]

Ma, Y.; Zhang, L.; Wu, Y.; Zhou, P. Changes in milk fat globule membrane proteome after pasteurization in human, bovine and caprine species. *Food Chem.* 2019, 279, 209–215. [CrossRef]

Yu, S.; Zhao, Z.-H.; Sun, L.; Li, P. Fermentation Results in Quantitative Changes in Milk-Derived Exosomes and Different Effects on Cell Growth and Survival. *J. Agric. Food Chem.* 2017, 65, 1220–1228. [CrossRef]
227. Aqil, F.; Munagala, R.; Jeyabalan, J.; Agrawal, A.; Kyakulaga, A.-H.; Wilcher, S.A.; Gupta, R.C. Milk exosomes—Natural
223. Manca, S.; Upadhyaya, B.; Mutai, E.; Desaulniers, A.T.; Cederberg, R.A.; White, B.; Zempleni, J. Milk exosomes are bioavailable
225. Tong, L.; Hao, H.; Zhang, X.; Zhang, Z.; Lv, Y.; Zhang, L.; Yi, H. Oral Administration of Bovine Milk-Derived Extracellular Vesicles
219. Kleinjan, M.; van Herwijnen, M.J.; Libregts, S.F.; van Neerven, R.J.; Feitsma, A.L.; Wauben, M.H. Regular Industrial Processing of
214. Auerbach, A.; Vyas, G.; Li, A.; Halushka, M.; Witwer, K.W. Uptake of dietary milk miRNAs by adult humans: A validation study.
213. Agrawal, A.; Aqil, F.; Jeyabalan, J.; Spencer, W.A.; Beck, J.; Gachuki, B.W.; Alhakeem, S.; Oben, K.; Munagala, R.; Bondada, S.; et al.
212. Munagala, R.; Aqil, F.; Jeyabalan, J.; Gupta, R.C. Bovine milk-derived exosomes for drug delivery.
210. Kusuma, R.J.; Manca, S.; Friemel, T.; Sukreet, S.; Nguyen, C.; Zempleni, J. Human vascular endothelial cells transport foreign
209. Wolf, T.; Baier, S.R.; Zempleni, J. The Intestinal Transport of Bovine Milk Exosomes Is Mediated by Endocytosis in Human Colon
208. Shandilya, S.; Rani, P.; Onteru, S.K.; Singh, D. Small Interfering RNA in Milk Exosomes Is Resistant to Digestion and Crosses the
207. Zhao, Z.; Yu, S.; Xu, M.; Li, P. Effects of microwave on extracellular vesicles and microRNA in milk. [CrossRef] [PubMed]
206. Izumi, H.; Kosaka, N.; Shimizu, T.; Sekine, K.; Ochiya, T.; Takase, M. Bovine milk contains microRNA and messenger RNA that
205. Baddela, V.S.; Nayan, V.; Rani, P.; Onteru, S.K.; Singh, D. Physicochemical Biomolecular Insights into Buffalo Milk-Derived Extracellular Vesicles.
203. Maburutse, B.E.; Park, M.-R.; Oh, S.; Kim, Y. Evaluation and Characterization of Milk-derived Microvesicle Isolated from Bovine Colostrum. Food Sci. Anim. Resour. 2017, 37, 654–662. [CrossRef]
202. Kosaka, N.; Izumi, H.; Sekine, K.; Ochiya, T. microRNA as a new immune-regulatory agent in breast milk. Silence 2010, 1, 7. [CrossRef]
201. Kirchner, B.; Buschmann, D.; Paul, V.; Pfäffli, M.W. Postprandial transfer of colostral extracellular vesicles and their protein and miRNA cargo in neonatal calves. PLoS ONE 2020, 15, e0229606. [CrossRef] [PubMed]
200. Gonzalez, M.I.; Martin-Duque, P.; Desco, M.; Salinas, B. Radioactive Labeling of Milk-Derived Exosomes with 99mTc and In Vivo Tracking by SPECT Imaging. Nanomaterials 2020, 10, 1062. [CrossRef] [PubMed]
199. Kleinjan, M.; van Herwijnen, M.J.; Libregts, S.F.; van Neerven, R.J.; Feitsma, A.L.; Wauben, M.H. Regular Industrial Processing of Bovine Milk Impacts the Integrity and Molecular Composition of Extracellular Vesicles. J. Nutr. 2021, 151, 1416–1425. [CrossRef] [PubMed]
198. Hansen, M.S.; Gadegaard, I.S.E.; Arnspong, E.C.; Blans, K.; Nejsum, L.N.; Rasmussen, J.T. Specific and Non-Invasive Fluorescent Labelling of Extracellular Vesicles for Evaluation of Intracellular Processing by Intestinal Epithelial Cells. Biomedicines 2020, 8, 211. [CrossRef] [PubMed]
197. Kirchner, B.; Buschmann, D.; Paul, V.; Pfäffli, M.W. Postprandial transfer of colostral extracellular vesicles and their protein and miRNA cargo in neonatal calves. PLoS ONE 2020, 15, e0229606. [CrossRef] [PubMed]
196. Sadri, M.; Shu, J.; Kachman, S.D.; Cui, J.; Zempleni, J. Milk exosomes and miRNA cross the placenta and promote embryo survival in mice. Reproduction 2020, 160, 501–509. [CrossRef]
195. Manca, S.; Upadhyaya, B.; Mutai, E.; Desaulniers, A.T.; Cederberg, R.A.; White, B.; Zempleni, J. Milk exosomes are bioavailable and distinct microRNA cargos have unique tissue distribution patterns. Sci. Rep. 2018, 8, 1–11. [CrossRef] [PubMed]
194. González, M.; González-Arjona, M.; Santos-Cooquillat, A.; Vaquero, J.; Vázquez-Ogado, E.; de Molina, A.; Peinado, H.; Desco, M.; Salinas, B. Covalently Labeled Fluorescent Exosomes for In Vitro and In Vivo Applications. Biomedicines 2021, 9, 81. [CrossRef] [PubMed]
193. Tong, L.; Hao, H.; Zhang, X.; Zhang, Z.; Ly, Y.; Zhang, L.; Yi, H. Oral Administration of Bovine Milk-Derived Extracellular Vesicles Alters the Gut Microbiota and Enhances Intestinal Immunity in Mice. Mol. Nutr. Food Res. 2020, 64, e1901251. [CrossRef] [PubMed]
192. Vashishat, M.; Rani, P.; Onteru, S.K.; Singh, D. Curcumin Encapsulated in Milk Exosomes Resists Human Digestion and Possesses Enhanced Intestinal Permeability in Vitro. Appl. Biochem. Biotechnol. 2017, 183, 993–1007. [CrossRef]
191. Agil, F.; Munagala, R.; Jeyabalan, J.; Agrawal, A.; Kyakulaga, A.-H.; Wilcher, S.A.; Gupta, R.C. Milk exosomes—Natural nanoparticles for siRNA delivery. Cancer Lett. 2019, 449, 186–195. [CrossRef] [PubMed]
190. Mudd, A.M.; Gu, T.; Munagala, R.; Jeyabalan, J.; Egilmez, N.K.; Gupta, R.C. Chemoprevention of Colorectal Cancer by Anthocyanidins and Mitigation of Metabolic Shifts Induced by Dysbiosis of the Gut Microbiome. Cancer Prev. Res. 2019, 13, 41–52. [CrossRef] [PubMed]
229.  Betker, J.L.; Angle, B.M.; Graner, M.W.; Anchordoquy, T.J. The Potential of Exosomes from Cow Milk for Oral Delivery. *J. Pharm. Sci.* 2019, 108, 1496–1505. [CrossRef]

230.  Shandilya, S.; Rani, P.; Oneteru, S.K.; Singh, D. Natural ligand-receptor mediated loading of siRNA in milk derived exosomes. *J. Biotechnol.* 2020, 318, 1–9. [CrossRef]

231.  Aqil, F.; Kausar, H.; Agrawal, A.; Jeyabalan, J.; Kyakulaga, A.-H.; Munagala, R.; Gupta, R. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. *Exp. Mol. Pathol.* 2016, 101, 12–21. [CrossRef]

232.  Nordgren, T.M.; Heires, A.J.; Zempleni, J.; Swanson, B.J.; Wichman, C.; Romberger, D.J. Bovine milk-derived extracellular vesicles enhance inflammation and promote M1 polarization following agricultural dust exposure in mice. *J. Nutr. Biochem.* 2019, 64, 110–120. [CrossRef]

233.  Pieters, B.C.H.; Arntz, O.J.; Bennink, M.B.; Broeren, M.; van Caam, A.; Koenders, M.I.; Van Lent, P.L.E.M.; Berg, W.B.V.D.; De Vries, M.; Van Der Kraan, P.M.; et al. Commercial Cow Milk Contains Physically Stable Extracellular Vesicles Expressing Immunoregulatory TGF-β. *PLoS ONE* 2015, 10, e0121123. [CrossRef]

234.  Maji, S.; Yan, I.K.; Parasaruramka, M.; Mohankumar, S.; Matsuda, A.; Patel, T. In vitrotoxicology studies of extracellular vesicles. *J. Appl. Toxicol.* 2016, 37, 310–318. [CrossRef] [PubMed]

235.  Näslund, T.I.; Proulx, D.P.; Paredes, P.T.; Vallhov, H.; Sandberg, J.; Gabrielsson, S. Exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells. *AIDS* 2014, 28, 171–180. [CrossRef]

236.  Matic, S.; D’Souza, D.H.; Wu, T.; Pangloli, P.; Dia, V.P.; Pangloli, P.; D’Souza, D.H.; Wu, T.; Pangloli, P.; Dia, V.P.; Bovine Milk Exosomes Affect Proliferation and Protect Macrophages against Cisplatin-Induced Cytotoxicity. *Immunol. Invest.* 2020, 49, 711–725. [CrossRef]

237.  Stremmel, W.; Weiskirchen, R.; Melnik, B.C. Milk Exosomes Prevent Intestinal Inflammation in a Genetic Mouse Model of Ulcerative Colitis: A Pilot Experiment. *Inflamm. Intest. Dis.* 2020, 5, 117–123. [CrossRef]

238.  Arntz, O.J.; Pieters, B.C.; Oliveira, M.; Broeren, M.; Bennink, M.B.; De Vries, M.; Van Lent, P.L.; Koenders, M.I.; Berg, W.B.V.D.; Van Der Kraan, P.M.; et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. *Mol. Nutr. Food Res.* 2015, 59, 1701–1712. [CrossRef]

239.  Miyake, H.; Lee, C.; Chusilp, S.; Bhalla, M.; Li, B.; Pitino, M.; See, S.; O’Connor, D.; Pierro, A. Human breast milk exosomes attenuate intestinal damage. *Pediatr. Surg. Int.* 2019, 36, 155–163. [CrossRef]

240.  Martin, C.; Patel, M.; Williams, S.; Arora, H.; Sims, B. Human breast milk-derived exosomes attenuate cell death in intestinal epithelial cells. *Innate Immun.* 2018, 24, 278–284. [CrossRef]

241.  Reif, S.; Elbaum-Shiff, Y.; Koroukhov, N.; Shilo, I.; Musseri, M.; Golan-Gerstl, R. Cow and Human Milk-Derived Exosomes Ameliorate Colitis in DSS Murine Model. *Nutrients* 2020, 12, 2589. [CrossRef]

242.  Li, B.; Hock, A.; Wu, R.Y.; Minich, A.; Botts, S.; Lee, C.; Antounians, L.; Miyake, H.; Koike, Y.; Chen, Y.; et al. Bovine milk-derived exosomes enhance goblet cell activity and prevent the development of experimental necrotizing enterocolitis. *PLoS ONE* 2019, 14, e0211431. [CrossRef]

243.  Hock, A.; Miyake, H.; Li, B.; Lee, C.; Ermini, L.; Koike, Y.; Chen, Y.; Määttänen, P.; Zani, A.; Pierro, A. Breast milk-derived exosomes promote intestinal epithelial cell growth. *J. Pediatr. Surg.* 2017, 52, 755–759. [CrossRef]

244.  Qin, W.; Tsukasaki, Y.; Dasgupta, S.; Mukhopadhyay, N.; Ikebe, M.; Sauter, E.R. Exosomes in Human Breast Milk Promote EMT. *Clin. Cancer Res.* 2016, 22, 4512–4524. [CrossRef]

245.  Leiferman, A.; Shu, J.; Grove, R.; Cui, J.; Adamec, J.; Zempleni, J. A diet defined by its content of bovine milk exosomes and their RNA cargos has moderate effects on gene expression, amino acid profiles and grip strength in skeletal muscle in C57BL/6 mice. *J. Nutr. Biochem.* 2018, 59, 123–128. [CrossRef]

246.  Mobley, C.B.; Mumford, P.; McCarthy, J.J.; Miller, M.E.; Young, K.C.; Martin, J.S.; Beck, D.T.; Lockwood, C.; Roberts, M.D. Whey protein-derived exosomes increase protein synthesis and hypertrophy in C2C12 myotubes. *J. Dairy Sci.* 2017, 100, 48–64. [CrossRef]

247.  Paredes, P.T.; Gutzeit, C.; Johansson, S.; Admyre, C.; Stenius, F.; Alm, J.; Scheynius, A.; Gabrielsson, S. Differences in exosome populations in human breast milk in relation to allergic sensitization and lifestyle. *Allergy* 2014, 69, 463–471. [CrossRef]

248.  Oliveira, M.; Di Ceglie, I.; Arntz, O.J.; Berg, W.B.V.D.; Hoogen, F.H.J.V.D.; Ferreira, A.; Van Lent, P.L.; Van De Loo, F.A. Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption. *J. Cell Physiol.* 2016, 232, 225–233. [CrossRef]

249.  Oliveira, M.C.; Pieters, B.C.H.; Guimarães, P.B.; Duffles, L.F.; Heredia, J.E.; Silveira, A.L.M.; Oliveira, A.C.C.; Teixeira, M.M.; Ferreira, A.V.M.; Silva, T.A.; et al. Bovine Milk Extracellular Vesicles Are Osteoprotective by Increasing Osteocyte Numbers and Targeting RANKL/OPG System in Experimental Models of Bone Loss. *Front. Bioeng. Biotechnol.* 2020, 8, 891. [CrossRef] [PubMed]

250.  Golan-Gerstl, R.; Shiff, Y.E.; Moshayoff, V.; Schecter, D.; Leshkowitz, D.; Reif, S. Characterization and biological function of milk-derived miRNAs. *Mol. Nutr. Food Res.* 2017, 61. [CrossRef] [PubMed]

251.  Yu, S.; Zhao, Z.-H.; Xu, X.; Li, M.; Li, P. Characterization of three different types of extracellular vesicles and their impact on bacterial growth. *Food Chem.* 2019, 272, 372–378. [CrossRef]

252.  Badawy, A.A.; El-Magd, M.A.; AlSadrah, S. Therapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo. *Integr. Cancer Ther.* 2018, 17, 1235–1246. [CrossRef] [PubMed]

253.  Jeyaram, A.; Jay, S.M. Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications. *AAPS J.* 2017, 20, 1–7. [CrossRef]
254. Civra, A.; Francese, R.; Donalisio, M.; Tonetto, P.; Coscia, A.; Sottemano, S.; Balestrini, R.; Faccio, A.; Cavallarin, L.; Moro, G.E.; et al. Human Colostrum and Derived Extracellular Vesicles Prevent Infection by Human Rotavirus and Respiratory Syncytial Virus in Vitro. *J. Hum. Nutr. Clin. Med.* 2021, 37, 122–134. [CrossRef]

255. Francese, R.; Civra, A.; Donalisio, M.; Volpi, N.; Capitani, F.; Sottemano, S.; Tonetto, P.; Coscia, A.; Maiocco, G.; Moro, G.E.; et al. Anti-Zika virus and anti-Usutu virus activity of human milk and its components. *PLoS Negl. Trop. Dis.* 2020, 14, e0008713. [CrossRef]

256. Hu, Y.; Hell, L.; Kendlbacher, R.A.; Hajji, N.; Hau, C.; van Dam, A.; Berckmans, R.J.; Wisgrill, L.; Ay, C.; Pabinger, I.; et al. Human milk triggers coagulation via tissue factor-exposing extracellular vesicles. *Blood Adv.* 2020, 4, 6274–6282. [CrossRef] [PubMed]

257. Pisano, C.; Galley, J.; Elbahravry, M.; Wang, Y.; Farrell, A.; Briggstock, D.; Besner, G.E. Human Breast Milk-Derived Extracellular Vesicles in the Protection Against Experimental Necrotizing Enterocolitis. *J. Pediatr. Surg.* 2020, 55, 54–58. [CrossRef]

258. Ascanius, S.; Hansen, M.; Ostenfeld, M.; Rasmussen, J. Milk-Derived Extracellular Vesicles Suppress Inflammatory Cytokine Expression and Nuclear Factor-κB Activation in Lipopolysaccharide-Stimulated Macrophages. *Dairy Sci. 2021*, 2, 165–178. [CrossRef]

259. Go, G.; Jeon, J.; Lee, G.; Lee, J.H.; Lee, S.H. Bovine milk extracellular vesicles induce the proliferation and differentiation of osteoblasts and promote osteogenesis in rats. *J. Food Biochem.* 2021, 45, e13705. [CrossRef]

260. Maghraby, M.K.; Li, B.; Chi, L.; Ling, C.; Benoussa, A.; Provost, P.; Postmus, A.C.; Abdi, A.; Pierro, A.; Bourdon, C.; et al. Extracellular vesicles isolated from milk can improve gut barrier dysfunction induced by malnutrition. *Sci. Rep.* 2021, 11, 7635. [CrossRef] [PubMed]

261. Carobolante, G.; Mantaj, J.; Ferrari, E.; Vlasaliu, D. Cow Milk and Intestinal Epithelial Cell-Derived Extracellular Vesicles as Systems for Enhancing Oral Drug Delivery. *Pharmaceutics* 2020, 12, 226. [CrossRef]

262. Parry, H.A.; Mobley, C.B.; Mumford, P.; Romero, M.A.; Haun, C.T.; Zhang, Y.; Roberson, P.A.; Zemleni, J.; Ferrando, A.A.; Vechetti, I.J.J.; et al. Bovine Milk Extracellular Vesicles (EVs) Modification Elicits Skeletal Muscle Growth in Rats. *Front. Physiol.* 2019, 10, 436. [CrossRef]

263. Oliveira, M.; Arntz, O.J.; Davidson, E.N.B.; van Lent, P.L.; Koenders, M.I.; van der Kraan, P.M.; Berg, W.B.V.D.; Ferreira, A.; van de Loo, F.A. Milk extracellular vesicles accelerate osteoblastogenesis but impair bone matrix formation. *J. Nutr. Biochem.* 2016, 30, 74–84. [CrossRef]

264. Del Pozo-Acebo, L.; López de las Hazas, M.-C.; Tomé-Carneiro, J.; Gil-Cabreroiz, P.; San-Cristobal, R.; Busto, R.; Garcia-Ruiz, A.; Dávalos, A. Bovine milk-derived exosomes as a drug delivery vehicle for miRNA-based therapy. *Int. J. Mol. Sci.* 2021, 22, 1105. [CrossRef] [PubMed]

265. Komine-Aizawa, S.; Ito, S.; Aizawa, S.; Namiki, T.; Hayakawa, S. Cow milk exosomes activate NK cells and γδT cells in human PBMCs in vitro. *Immunol. Med.* 2020, 43, 161–170. [CrossRef] [PubMed]

266. Maghraby, M.K.H.A. Using Milk-Derived Exosomes to Repair Malnutrition-Induced Gut Barrier Dysfunction in Mice; University of Toronto: Toronto, ON, Canada, 2020.

267. Wang, L.; Shi, Z.; Wang, X.; Mu, S.; Xu, X.; Shen, L.; Li, P. Protective effects of bovine milk exosomes against oxidative stress in IEC-6 cells. *Eur. J. Nutr.* 2020, 60, 317–327. [CrossRef]

268. Yun, B.; Maburutse, B.; Kang, M.; Park, M.; Park, D.; Kim, Y.; Oh, S. Short communication: Dietary bovine milk–derived exosomes improve bone health in an osteoporosis-induced mouse model. *J. Dairy Sci.* 2020, 103, 7752–7760. [CrossRef]

269. Wu, D.; Kittana, H.; Shu, J.; Kachman, S.D.; Cui, J.; Ramer-Tait, A.E.; Zemleni, J. Dietary depletion of milk exosomes and their microRNA cargos elicits a depletion of miR-200a-3p and elevated intestinal inflammation and chemokine (C-X-C motif) ligand 9 expression in *Mdr1a*−/− mice. *Curr. Dev. Nutr.* 2019, 3. [CrossRef]

270. Gao, H.; Guo, H.; Zhang, H.; Xie, X.; Wen, P.; Ren, F. Yak-milk-derived exosomes promote proliferation of intestinal epithelial cells in an hypoxic environment. *J. Dairy Sci.* 2019, 102, 985–996. [CrossRef]

271. Xie, M.-Y.; Chen, T.; Xi, Q.-Y.; Hou, L.-J.; Luo, J.-Y.; Zeng, B.; Li, M.; Sun, J.-J.; Zhang, Y.-L. Porcine milk exosome miRNAs protect intestinal epithelial cells against deoxynivalenol-induced damage. *Biochem. Pharmacol.* 2020, 175, 113898. [CrossRef]

272. Chen, T.; Xie, M.-Y.; Sun, J.-J.; Ye, R.-S.; Cheng, X.; Sun, R.-P.; Wei, L.-M.; Li, M.; Lin, D.-L.; Jiang, Q.-Y.; et al. Porcine milk-derived exosomes promote proliferation of intestinal epithelial cells. *Sci. Rep.* 2016, 6, 38362. [CrossRef]

273. Pietrzak-Fiecko, R.; Kamelska-Sadowska, A.M. The Comparison of Nutritional Value of Human Milk with Other Mammals' Milk. *Nutrients* 2020, 12, 1404. [CrossRef]

274. Roy, D.; Ye, A.; Moughan, P.J.; Singh, H. Composition, Structure, and Digestive Dynamics of Milk from Different Species—A Review. *Front. Nutr.* 2020, 7, 577759. [CrossRef]